2021/12/21 更新

写真a

オオニシ ヒデキ
大西 秀樹
ONISHI Hideki
所属
岡山大学病院 講師
職名
講師
外部リンク

学位

  • 医学博士 ( 2010年9月   岡山大学大学院 )

研究キーワード

  • 化学療法

  • 画像診断

  • 肝細胞癌

研究分野

  • ライフサイエンス / 消化器内科学  / 肝細胞癌

学歴

  • 岡山大学大学院   医歯学総合研究科   病態制御学専攻

    2003年4月 - 2010年9月

      詳細を見る

  • 岡山大学   Medical School   Faculty of Medicine

    1991年4月 - 1997年3月

      詳細を見る

    国名: 日本国

    researchmap

経歴

  • 岡山大学病院   消化器内科   講師

    2019年4月 - 現在

      詳細を見る

    国名:日本国

    researchmap

所属学協会

  • 日本超音波医学会

    2009年10月 - 現在

      詳細を見る

  • 日本肝臓学会

    2003年10月 - 現在

      詳細を見る

  • 日本糖尿病学会

    1997年12月 - 現在

      詳細を見る

  • 日本消化器病学会

    1997年6月 - 現在

      詳細を見る

  • 日本内科学会

    1997年6月 - 現在

      詳細を見る

委員歴

  • 日本消化器病学会   学会評議員  

    2020年1月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本超音波医学会   中国地方会運営委員  

    2018年6月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本内科学会   中国支部評議員  

    2017年6月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本消化器病学会   中国支部評議員  

    2015年1月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

 

論文

  • A case of focal nodular hyperplasia with hepatic failure treated with liver transplantation.

    Tetsuya Yasunaka, Yasuto Takeuchi, Akinobu Takaki, Fukuo Kondo, Tomoharu Yoshizumi, Kenichi Kohashi, Atsushi Oyama, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Hiroyuki Okada

    Clinical journal of gastroenterology   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Focal nodular hyperplasia (FNH) is a benign nodular lesion, but because of its feature of portal tract vessel abnormality, it may induce portal hypertension. A 27-year-old woman was admitted with a fever. A large nodule with satellite lesions was found in the liver and cotton wool-like feature of arteries were detected on angiography. Technetium galactosyl serum albumin scintigraphy and diagnostic laparoscopy showed that the tumor site was functional, while the surrounding area was a non-functional fibrotic area. A biopsy specimen indicated that the nodular lesion was an FNH-like lesion. She experienced several instances of variceal rupture and suffered liver failure, receiving liver transplantation. The excised liver showed a centrally scarred area in the nodule, indicating that the diagnosis was FNH. We herein report this case as a rare case of FNH that progressed to liver failure.

    DOI: 10.1007/s12328-021-01529-w

    PubMed

    researchmap

  • 急性肝不全に陥ることなく致死的経過を辿った急性E型肝炎の1例

    山内 菜緒, 安中 哲也, 高木 章乃夫, 日並 義統, 木野村 賢, 河原 明奈, 足立 卓哉, 大山 淳史, 和田 望, 竹内 康人, 大西 秀樹, 白羽 英則, 岡田 裕之

    肝臓   62 ( 8 )   463 - 470   2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. 国際誌

    Atsushi Oyama, Kazuhiro Nouso, Kenichi Yoshimura, Yuki Morimoto, Shinichiro Nakamura, Hideki Onishi, Akinobu Takaki, Shouta Iwadou, Kazuya Kariyama, Kenji Kuwaki, Kazuhisa Yabushita, Kosaku Sakaguchi, Jyunichi Toshimori, Haruhiko Kobashi, Akio Moriya, Masaharu Ando, Hiroyuki Okada

    Hepatology research : the official journal of the Japan Society of Hepatology   51 ( 6 )   694 - 701   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin is beneficial to patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. This study aimed to examine the effect of HAIC with cisplatin before radiofrequency ablation (RFA) in patients with HCC. METHODS: This was a multicenter, single-blinded, randomized controlled study (UMIN000007267). Early-stage HCC patients were randomly assigned (1:1) to receive HAIC with cisplatin before RFA therapy (HAIC group) or RFA monotherapy (non-HAIC group). The primary end-point was recurrence-free survival. Efficacy analysis and safety analysis followed the intention-to-treat principle. RESULTS: Between August 2012 and July 2016, 74 patients were recruited. A total of 70 eligible patients were randomly assigned to the HAIC group (n = 35) and non-HAIC group (n = 35). Recurrence-free survival rates at 1 (3) year in the HAIC group and non-HAIC group were 82.9% (54.3%) and 74.3% (34.3%), respectively (hazard ratio [HR], 0.597; 95% confidence interval [CI], 0.320-1.091; p = 0.094]. Subgroup analysis showed that the beneficial effect of HAIC was observed in patients with a single nodule and Child-Pugh score 5. Intrahepatic distant recurrence-free survival rate in the HAIC group was significantly better than that in the non-HAIC group (HR, 0.468; 95% CI, 0.235-0.896; p = 0.022). Adverse events were observed in just two patients in the HAIC group (6%) - grade 2 cholecystitis and grade 2 hyperkalemia. CONCLUSIONS: HAIC with cisplatin before RFA did not significantly decrease recurrence in patients with early-stage HCC. However, it might be effective in preventing intrahepatic distant recurrence.

    DOI: 10.1111/hepr.13633

    PubMed

    researchmap

  • Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. 国際誌

    Takuya Adachi, Yasuto Takeuchi, Akinobu Takaki, Atsushi Oyama, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Hiroyuki Okada

    International journal of molecular sciences   22 ( 11 )   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2. Given that liver cirrhosis patients exhibit hyponatremia due to their pseudo-aldosteronism and usage of natriuretic agents, a sodium maintaining agent, such as tolvaptan, is physiologically preferable. However, large scale studies indicating the patients for whom this would be effective and describing management under its use have been insufficient. The appropriate management of cirrhosis patients treated with tolvaptan should be investigated. In the present review, we collected articles investigating the effectiveness of tolvaptan and factors associated with survival and summarized their management reports. Earlier administration of tolvaptan before increasing the doses of natriuretic agents is recommended because this may preserve effective arterial blood volume.

    DOI: 10.3390/ijms22115582

    PubMed

    researchmap

  • Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis. 国際誌

    Kazuhiro Nouso, Yoshie Furubayashi, Kazuya Kariyama, Akiko Wakuta, Nozomi Miyake, Kanae Inoue, Yuta Nagai, Shiho Murakami, Takuya Adachi, Atsushi Oyama, Nozomu Wada, Yasuto Takeuchi, Masahiro Sakata, Tetsuya Yasunaka, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki, Shohei Shiota, Satoshi Yasuda, Hidenori Toyoda, Miwa Kawanaka, Takashi Kumada, Hiroyuki Okada

    Hepatology research : the official journal of the Japan Society of Hepatology   51 ( 5 )   548 - 553   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Nonalcoholic steatohepatitis (NASH) is a risk factor for nonvirus-related hepatocellular carcinoma, which is increasing in prevalence. The aim of this study was to clarify the clinical application of fucosylated alpha-fetoprotein (AFP-L3) in the process of nonalcoholic fatty liver (NAFL) disease development. METHODS: Serum samples from 115 diabetes mellitus (DM), 36 NAFL, and 119 NASH patients were analyzed for AFP-L3 expression using raw data of a micro total analysis system. These data were then compared with the clinical characteristics of the patients. A validation study was also undertaken with 55 samples (17 NAFL and 38 NASH). RESULTS: Trace amounts of AFP-L3 were detected in 3.5%, 16.7%, and 58.0% of patients with DM, NAFL, and NASH, respectively. The odds ratio of AFP-L3 positivity for the diagnosis of NASH in multivariate analysis was 9.81 (95% confidence interval, 3.77-25.5). The rates in patients without fibrosis or with stage 1, stage 2, stage 3, and stage 4 fibrosis were 14.7%, 31.3%, 63.0%, 86.2%, and 100%, respectively. The rates were significantly increased according to the advancement of liver fibrosis (p < 0.001); however, no difference in the positive rate of AFP-L3 was observed between patients with and without fatty livers and between patients with normal and abnormal transaminase. The same relationship was also observed in the validation cohort. CONCLUSION: Abnormal fucosylation of AFP occurred in patients with NASH, so it could be useful for the screening of NASH in patients with DM, as well as for the differential diagnosis of NASH and the evaluation of fibrosis.

    DOI: 10.1111/hepr.13626

    PubMed

    researchmap

  • Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. 国際誌

    Mami Hirai, Hideaki Kinugasa, Kazuhiro Nouso, Shumpei Yamamoto, Hiroyuki Terasawa, Yuma Onishi, Atsushi Oyama, Takuya Adachi, Nozomu Wada, Masahiro Sakata, Tetsuya Yasunaka, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    Journal of gastroenterology and hepatology   36 ( 4 )   1118 - 1125   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND ANDAIM: Human telomerase reverse transcriptase (TERT) promoter mutations were the most prevalent mutations in patients with hepatocellular carcinoma (HCC). We tried to detect the mutations with plasma circulating tumor DNA (ctDNA) in patients with advanced HCC and elucidated their clinical utility. METHODS: Circulating tumor DNA in plasma was extracted from 130 patients with advanced HCC who were treated with systemic chemotherapy (n = 86) or transcatheter arterial chemoembolization (n = 44), and TERT promoter mutations were examined with digital droplet polymerase chain reaction. The correlations between these mutations and the clinical outcome of patients were analyzed. RESULTS: Of the 130 patients examined, 71 patients (54.6%) were positive for TERT promoter mutations in ctDNA, of which 64 patients were -124bp G > A and 10 were -146bp G > A. The presence of TERT promoter mutations was correlated with large intrahepatic tumor size (P = 0.05) and high des-gamma carboxyprothrombin (P = 0.005). Overall survival of the patients with the mutations was significantly shorter than those without them (P < 0.001), and the patients with high (≥ 1%) fractional abundance of the mutant alleles showed shorter survival than those with low (< 1%) fractional abundance. Multivariate analysis revealed that TERT promoter mutation (hazard ratio [HR]: 1.94; 95% confidence interval [CI], 1.18-3.24; P < 0.01), systemic chemotherapy (HR: 2.38; 95% CI, 1.29-4.57; P < 0.01), and vascular invasion (HR: 2.16; 95% CI, 1.22-3.76; P < 0.01) were significant factors for poor overall survival. CONCLUSIONS: TERT promoter mutations in ctDNA were associated with short survival and could be a valuable biomarker for predicting the prognosis of patients with advanced HCC.

    DOI: 10.1111/jgh.15227

    PubMed

    researchmap

  • High expression of a vascular stricture-related marker is predictive of an early response to tolvaptan, and a low fractional excretion of sodium is predictive of a poor long-term survival after tolvaptan administration for liver cirrhosis. 国際誌

    Takuya Adachi, Akinobu Takaki, Shuichi Sato, Hiroshi Tobita, Haruhiko Kobashi, Masaru Kinomura, Atsuko Nakatsuka, Atsushi Oyama, Nozomu Wada, Masahiro Sakata, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Onishi, Hidenori Shiraha, Hiroyuki Okada

    Hepatology research : the official journal of the Japan Society of Hepatology   50 ( 12 )   1347 - 1354   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Tolvaptan is a newly available diuretic that has a specific function in water reabsorption inhibition. Given that spironolactone or furosemide induces the aggravation of cirrhotic hyponatremia and dehydration, tolvaptan affects the management strategy of liver cirrhosis. Representative predictive markers of its response include renal function-related markers such as urea nitrogen or creatinine. However, vascular function-related markers have not been well investigated. We investigated the effect of the vascular function-related marker asymmetric dimethylarginine (ADMA) and the effective arterial blood volume (EABV) marker, fractional excretion of sodium (FENa), on the early tolvaptan response and survival in liver cirrhosis. METHODS: We prospectively recruited 49 patients who required add-on tolvaptan for refractory ascites or edema. Laboratory data were obtained immediately before and 1 day after tolvaptan administration. Patients exhibiting >1.5 kg weight loss after 1 week were categorized as early responders to tolvaptan. Patients were followed for a median of 200 days and were assessed for survival. RESULTS: Early responders showed lower creatinine levels (<1.0 mg/dL), and higher ADMA levels (≥0.61 nmol/mL) than others in a multivariate analysis. Patients with a shorter survival were positive for hepatocellular carcinoma and had a low FENa (<0.35%). CONCLUSION: Early responders showed higher ADMA levels reflecting vascular stricture, suggesting that higher vascular tonus is required for a tolvaptan early response. Patients with a shorter survival showed a lower FENa, reflecting a lower EABV and suggesting that adequate EABV is required for the prolonged survival after tolvaptan administration.

    DOI: 10.1111/hepr.13573

    PubMed

    researchmap

  • Residual Restrictive Right Ventricular Physiology after One-and-a-Half Ventricular Repair Conversion in Pulmonary Atresia with Intact Ventricular Septum. 国際誌

    Kazuki Suruga, Norihisa Toh, Yasuhiro Kotani, Hideki Onishi, Teiji Akagi, Shingo Kasahara, Hiroshi Ito

    CASE (Philadelphia, Pa.)   4 ( 6 )   523 - 525   2020年12月

     詳細を見る

  • Decreased Serum Antioxidant Marker is Predictive of Early Recurrence in the Same Segment after Radical Ablation for Hepatocellular Carcinoma.

    Taiko Muro, Shinichiro Nakamura, Akinobu Takaki, Hideki Onishi, Nozomu Wada, Tetsuya Yasunaka, Daisuke Uchida, Atsushi Oyama, Takuya Adachi, Hidenori Shiraha, Hiroyuki Okada

    Acta medica Okayama   74 ( 4 )   275 - 283   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a promising method for controlling tumors, although it does not entirely eliminate recurrence. Oxidative stress is associated with the progression of hepatocarcinogenesis, while also acting as an anticancer response. The objective of the present study was to investigate the factors influencing post-RFA outcomes. We recruited 235 newly diagnosed HCC patients who received RFA for single tumors. The patients with recurrence were sub-grouped into early and segmental recurrence groups. The characteristics of the sub-grouped patients were evaluated, including by measuring oxidative stress marker reactive oxygen metabolites and antioxidant marker OXY-adsorbent tests. The factors associated with poor survival were a high Child-Pugh score and early recurrence within 2 years in the same segment. The patients who experienced recurrence within 2 years in the same segment showed a larger tumor diameter than did others. According to a multivariate analysis, the OXY values were also significantly low in these patients. In conclusion, maintaining the antioxidant reservoir function with a high OXY value might be necessary to prevent early recurrence within the RFA-treated segment.

    DOI: 10.18926/AMO/60364

    PubMed

    researchmap

  • The Early Decline of α-Fetoprotein and Des-γ-Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients. 国際誌

    Shumpei Yamamoto, Hideki Onishi, Akinobu Takaki, Atsushi Oyama, Takuya Adachi, Nozomu Wada, Masahiro Sakata, Tetsuya Yasunaka, Hidenori Shiraha, Hiroyuki Okada

    Gastrointestinal tumors   7 ( 3 )   83 - 92   2020年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Introduction: Molecular targeting drugs are recommended as second-line treatment for intrahepatic advanced hepatocellular carcinoma (HCC). However, in Asia, hepatic arterial infusion chemotherapy (HAIC) is also considered as a second-line treatment because it improves the survival of responders. The aim of this study was to predict responders and non-responders to HAIC with low-dose cisplatin plus 5-fluorouracil (LFP) using tumor markers. Objective and Methods: The data of 47 patients who received LFP for the first time in our hospital were analyzed retrospectively. We evaluated the association between treatment response by Response Evaluation Criteria in Solid Tumors and the changing ratio of the serum concentration of α-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and des-γ-carboxy prothrombin (DCP) 2 weeks after LFP initiation. Results: The number of patients showing a complete response (CR), a partial response (PR), stable disease (SD), and progressive disease (PD) was 0 (0%), 20 (43%), 18 (38%), and 9 (19%), respectively. The AFP ratio showed significant positive correlations for PR vs. SD (p = 0.004) and PR vs. PD (p = 0.003). The DCP ratio correlated significantly for PR vs. SD (p = 0.02). The optimal cutoff values for responders were 0.79 for the AFP ratio and 0.53 for the DCP ratio. Prediction using both or either cutoff value showed 93% sensitivity, 53% specificity, a 94% negative predictive value, and a 57% positive predictive value. Conclusion: Optimal cutoff values for AFP and DCP ratios enable prediction of nonresponders to HAIC with LFP. This simple and early assessment method allows the use of HAIC and molecular targeting drugs for HCC treatment.

    DOI: 10.1159/000506941

    PubMed

    researchmap

  • Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. 国際誌

    Daisuke Uchida, Akinobu Takaki, Atsushi Oyama, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hiroyuki Okada

    Nutrients   12 ( 6 )   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Chronic viral hepatitis B and C and non-alcoholic fatty liver disease (NAFLD) have been widely acknowledged to be the leading causes of liver cirrhosis and hepatocellular carcinoma. As anti-viral treatment progresses, the impact of NAFLD is increasing. NAFLD can coexist with chronic viral hepatitis and exacerbate its progression. Oxidative stress has been recognized as a chronic liver disease progression-related and cancer-initiating stress response. However, there are still many unresolved issues concerning oxidative stress, such as the correlation between the natural history of the disease and promising treatment protocols. Recent findings indicate that oxidative stress is also an anti-cancer response that is necessary to kill cancer cells. Oxidative stress might therefore be a cancer-initiating response that should be down regulated in the pre-cancerous stage in patients with risk factors for cancer, while it is an anti-cancer cell response that should not be down regulated in the post-cancerous stage, especially in patients using anti-cancer agents. Antioxidant nutrients should be administered carefully according to the patients' disease status. In this review, we will highlight these paradoxical effects of oxidative stress in chronic liver diseases, pre- and post-carcinogenesis.

    DOI: 10.3390/nu12061576

    PubMed

    researchmap

  • Severe Colitis Caused by Hepatic Arterial Infusion Chemotherapy with Cisplatin for Hepatocellular Carcinoma.

    Shumpei Yamamoto, Hideki Onishi, Atsushi Oyama, Akinobu Takaki, Hiroyuki Okada

    Internal medicine (Tokyo, Japan)   59 ( 1 )   69 - 75   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A 78-year-old man with chronic hepatitis C underwent hepatectomy for hepatocellular carcinoma (HCC) 11 years prior to presentation. He was diagnosed with multiple intrahepatic recurrences of HCC with portal vein invasion and received hepatic arterial infusion chemotherapy (HAIC) with cisplatin. He developed abdominal pain, diarrhea, and blood-stained stool following treatment. Computed tomography revealed significant bowel wall thickening throughout the colon. Colonoscopy revealed reddish edematous mucosa with a reduced vascular pattern without ischemic changes. Conservative treatment with total parenteral nutrition improved his condition and his imaging findings. This is the first report of severe colitis following HAIC with cisplatin.

    DOI: 10.2169/internalmedicine.3340-19

    PubMed

    researchmap

  • Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma. 国際誌

    Soichiro Ako, Kazuhiro Nouso, Hideaki Kinugasa, Hiroshi Matsushita, Hiroyuki Terasawa, Takuya Adachi, Nozomu Wada, Yasuto Takeuchi, Mari Mandai, Hideki Onishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Shinichi Fujioka, Tetsushige Mimura, Hiroyuki Okada

    Oncology   98 ( 5 )   311 - 317   2020年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Mutations in the human telomerase reverse transcriptase (hTERT) gene promoter have been reported in hepatocellular carcinoma (HCC); however, analyses of these mutations in liquid biopsies have been technically difficult because of the high GC content of the regions of interest within this promoter. We evaluated the feasibility and prognostic value of hTERT promoter mutations identified in circulating cell-free DNA (cfDNA) from the serum of patients with HCC. OBJECTIVE: A cohort of HCC patients (n = 36) who were curatively treated by surgical resection between June 2003 and September 2014 were enrolled in this study. METHODS: The presence of hTERT promoter mutations in cfDNA from the patients' serum was analyzed via modified droplet digital polymerase chain reaction, and associations were sought between specific promoter mutations and patients' disease-free survival (DFS). RESULTS: The G>A hTERT mutation at -124 bp was detected in the serum of 25 patients (69%). Although no marked differences were observed between the characteristics of the serum mutation-positive and serum mutation-negative patient groups, the DFS of patients with the mutation was significantly shorter than that of the serum mutation-negative patients (p = 0.02). Among 18 clinicopathologic and background liver factors examined, the presence of the -124 bp G>A mutation was an independent and significant predictor of patients' DFS (hazard ratio = 3.01, 95% confidence interval 1.11-10.5, p = 0.03) in multivariate analyses. CONCLUSIONS: The -124 bp G>A hTERT promoter mutation was observed in the serum of 69% of HCC patients who underwent surgical resection and was an independent predictor of disease progression in HCC.

    DOI: 10.1159/000506135

    PubMed

    researchmap

  • A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol. 国際誌

    Astushi Oyama, Hidenori Shiraha, Daisuke Uchida, Masaya Iwamuro, Hironari Kato, Akinobu Takaki, Fusao Ikeda, Hideki Onishi, Tetsuya Yasunaka, Yasuto Takeuchi, Nozomu Wada, Yoshiaki Iwasaki, Masahiro Sakata, Hiroyuki Okada, Hiromi Kumon

    Future oncology (London, England)   15 ( 31 )   3547 - 3554   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This study will assess the safety and efficacy of the administration of adenoviral vector expressing the human-reduced expression in immortalized cells (Ad-REIC) to a liver tumor in patients with hepatocellular carcinoma (HCC) or liver metastasis of pancreatic cancer. A Phase I clinical study of Ad-REIC administration to a liver tumor in a patient with HCC or liver metastasis of pancreatic cancer will be conducted. The study is a single-arm, prospective, nonrandomized, noncomparative, open-label, single-center trial performed in Okayama University Hospital, Okayama, Japan. Ad-REIC will be injected into the liver tumor under ultrasound guidance. Ad-REIC administration will be repeated a total of three-times every 2 weeks. The primary end point is the dose-limiting toxicity and incidence of adverse events. The secondary end points are the objective response rate and disease control rate. This study aims to expand the indication of Ad-REIC by assessing its safety and efficacy in patients with HCC or liver metastasis of pancreatic cancer.

    DOI: 10.2217/fon-2019-0115

    PubMed

    researchmap

  • The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.

    Kenji Kuwaki, Kazuhiro Nouso, Manabi Miyashita, Yasuhiro Makino, Hiroaki Hagihara, Akio Moriya, Takuya Adachi, Nozomu Wada, Yuki Yasunaka, Tetsuya Yasunaka, Yasuto Takeuchi, Hideki Onishi, Shinichiro Nakamura, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    Acta medica Okayama   73 ( 4 )   333 - 339   2019年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Steroids are often administered at the time of transcatheter arterial chemoembolization (TACE), a standard treatment of hepatocellular carcinoma (HCC), with the expectation of preventing postembolization syndrome. Here we investigated the precise effects of steroids on TACE. We prospectively enrolled 144 HCC patients from 10 hospitals who underwent TACE. Three hospitals used steroids (steroid group, n=77) and the rest did not routinely use steroids (control group, n=67). The occurrence of adverse events and the algetic degree at 1-5 days post-treatment were compared between the groups. Fever (grades 0-2) after TACE was significantly less in the steroid group (56/21/0) compared to the control group (35/29/3, p=0.005, Cochran-Armitage test for trend). The suppressive effect of steroids against fever was prominent in females (p=0.001). Vomiting (G0/G1/ G2-) was also less frequent in the steroid group (70/5/2) versus the control group (53/10/3), but not significantly (p=0.106). The algetic degree and the grade of hematological adverse events, including hyperglycemia, did not differ between the groups. We conclude that the administration of steroids was useful for the prevention of adverse events after TACE in patients with HCC.

    DOI: 10.18926/AMO/56935

    PubMed

    researchmap

  • Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib. 国際誌

    Takuya Adachi, Kazuhiro Nouso, Koji Miyahara, Atsushi Oyama, Nozomu Wada, Chihiro Dohi, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Onishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Takabatake, Shin-Ichi Fujioka, Haruhiko Kobashi, Yoshitaka Takuma, Shouta Iwadou, Shuji Uematsu, Koichi Takaguchi, Hiroaki Hagihara, Hiroyuki Okada

    Journal of gastroenterology and hepatology   34 ( 6 )   1081 - 1087   2019年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one-time measurements before treatment. METHODS: We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. RESULTS: Among six significant risk factors for overall survival in univariate analyses, high angiopoietin-2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin-2 at the time of progressive disease was a marker of short post-progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression-free survival except the presence of hepatitis B virus surface antigen. CONCLUSIONS: Predictions of overall survival and post-progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin-2, in patients with HCC treated with sorafenib.

    DOI: 10.1111/jgh.14535

    PubMed

    researchmap

  • Predictive Factors for Successful Vaccination Against Hepatitis B Surface Antigen in Patients Who Have Undergone Orthotopic Liver Transplantation.

    Ailee Ikeda, Akinobu Takaki, Tetsuya Yasunaka, Atsushi Oyama, Takuya Adachi, Nozomu Wada, Hideki Onishi, Fusao Ikeda, Hidenori Shiraha, Kazuhiro Yoshida, Takashi Kuise, Daisuke Nobuoka, Ryuichi Yoshida, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Hiroyuki Okada

    Acta medica Okayama   73 ( 1 )   41 - 50   2019年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29% (8/28) of the LC-B group, 88% (7/8) of the ALF-B group, and 44% (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses.

    DOI: 10.18926/AMO/56457

    PubMed

    researchmap

  • [Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B].

    Takashi Makita, Hirotaka Kanzaki, Hideki Onishi, Ailee Ikeda, Akinobu Takaki, Nozomu Wada, Yasuto Takeuchi, Tetsuya Yasunaka, Fusao Ikeda, Hidenori Shiraha, Yuta Tanaka, Shigeki Nishihara, Kiminaka Murakawa, Yoshihisa Kitamura, Hiroyuki Okada, Toshiaki Sendo

    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan   139 ( 4 )   641 - 645   2019年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    We herein present the case of a 66-year-old Japanese man with Fanconi's syndrome. He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles. Renal dysfunction, hypophosphatemia, and increased levels of bone alkaline phosphatase were found by a hematology test after admission for treatment of HCC. Radiography and 99m Tc-labeled hydroxymethylene diphosphonate (HMDP) scintigraphy revealed multiple insufficiency fractures in the ribs, knees, ankles, and heels. After switching from ADV to tenofovir disoproxil fumarate (TDF) and treatment with calcitriol and sodium dihydrogenphosphate, the patient's serum phosphate levels slightly increased and renal dysfunction did not improve, but after six months his clinical symptoms disappeared. To detect and prevent adverse effects from ADV, physicians and pharmacists should carefully monitor renal function and serum phosphate levels in patients with hepatitis B virus (HBV) treated for a long time with ADV.

    DOI: 10.1248/yakushi.18-00170

    PubMed

    researchmap

  • 岡山県地域肝炎対策サポーター育成後の活動実態調査 肝炎医療コーディネーター活動と部署異動

    難波 志穂子, 池田 房雄, 秋山 文男, 石原 光将, 下村 泰之, 山崎 典子, 犬山 奈穂美, 小山 道弘, 亀川 勝典, 大久保 進之介, 長谷川 祐子, 岩井 賢司, 三喜 明子, 三浦 留美, 矢野 香苗, 藤井 洋輔, 大山 淳史, 足立 卓哉, 和田 望, 安中 幸, 安中 哲也, 大西 秀樹, 白羽 英則, 高木 章乃夫, 山野井 尚美, 岡田 裕之

    肝臓   59 ( 11 )   625 - 632   2018年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    岡山県では2011年より肝疾患に関わる部署の初任者を対象に肝炎医療研修会を実施し、受講者を地域肝炎対策サポーターと認定してきたが、厚生労働省の示す肝炎医療コーディネーターの役割を果たしているか不明であった。今回、認定者全員に調査票を郵送して、認定から現在までの肝炎に関する活動状況を調査した。地域肝炎対策サポーター298人中146人から回答を得た。回答者の56%が肝疾患関連部署に引き続き勤務し、3割が厚生労働省の示す肝炎医療コーディネーターの役割に合致することを確認した。回答者の24%は他部署へ異動していたが、その56%が日常業務と別に肝炎医療コーディネーター活動を行っており、部署の異動は非専門診療科に肝炎医療コーディネーター活動のできる人材を拡げる良い機会と考えられる。肝炎医療コーディネーターは医療圏の間で偏在を認めなかった。(著者抄録)

    researchmap

  • CTAPと出血シンチグラフィで診断し、経皮的硬化療法で止血し得た小腸静脈瘤出血の1例

    神尾 知宏, 川野 誠司, 大西 秀樹, 大林 由佳, 大山 淳史, 能祖 一裕, 原田 馨太, 岡田 裕之, 藤原 寛康, 金澤 右

    日本消化器病学会雑誌   115 ( 8 )   732 - 738   2018年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    症例は55歳、男性。複数の腹部手術歴や、食道静脈瘤に対して内視鏡的治療歴あり。突然の血便を認め緊急入院。大腸内視鏡を施行するも出血源は同定できず、CT during arterial portography(CTAP)を施行したところ、上腸間膜静脈から流入し腹壁静脈へと排血する小腸静脈瘤を認めた。経皮的に腹壁静脈を直接穿刺することで硬化療法を施行し、良好な止血を得られ、侵襲の高い外科手術を回避することができた。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J01118&link_issn=&doc_id=20180817330007&doc_link_id=130007432101&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130007432101&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  • A subclinical high tricuspid regurgitation pressure gradient independent of the mean pulmonary artery pressure is a risk factor for the survival after living donor liver transplantation. 国際誌

    Yosuke Saragai, Akinobu Takaki, Yuzo Umeda, Takashi Matsusaki, Tetsuya Yasunaka, Atsushi Oyama, Ryuji Kaku, Kazufumi Nakamura, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Kosei Takagi, Takuya Adachi, Nozomu Wada, Yasuto Takeuchi, Kazuko Koike, Fusao Ikeda, Hideki Onishi, Hidenori Shiraha, Shinichiro Nakamura, Hiroshi Morimatsu, Hiroshi Ito, Toshiyoshi Fujiwara, Takahito Yagi, Hiroyuki Okada

    BMC gastroenterology   18 ( 1 )   62 - 62   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Portopulmonary hypertension (POPH) is characterized by pulmonary vasoconstriction, while hepatopulmonary syndrome (HPS) is characterized by vasodilation. Definite POPH is a risk factor for the survival after orthotopic liver transplantation (OLT), as the congestive pressure affects the grafted liver, while subclinical pulmonary hypertension (PH) has been acknowledged as a non-risk factor for deceased donor OLT. Given that PH measurement requires cardiac catheterization, the tricuspid regurgitation pressure gradient (TRPG) measured by echocardiography is used to screen for PH and congestive pressure to the liver. We investigated the impact of a subclinical high TRPG on the survival of small grafted living donor liver transplantation (LDLT). METHODS: We retrospectively analyzed 84 LDLT candidates. Patients exhibiting a TRPG ≥25 mmHg on echocardiography were categorized as potentially having liver congestion (subclinical high TRPG; n = 34). The mean pulmonary artery pressure (mPAP) measured after general anesthesia with FIO20.6 (mPAP-FIO20.6) was also assessed. Patients exhibiting pO2 < 80 mmHg and an alveolar-arterial oxygen gradient (AaDO2) ≥ 15 mmHg were categorized as potentially having HPS (subclinical HPS; n = 29). The clinical course after LDLT was investigated according to subclinical high TRPG. RESULTS: A subclinical high TRPG (p = 0.012) and older donor age (p = 0.008) were correlated with a poor 40-month survival. Although a higher mPAP-FIO20.6 was expected to correlate with a worse survival, a high mPAP-FIO20.6 with a low TRPG was associated with high frequency complicating subclinical HPS and a good survival, suggesting a reduction in the PH pressure via pulmonary shunt. CONCLUSION: In cirrhosis patients, mPAP-FIO20.6 may not accurately reflect the congestive pressure to the liver, as the pressure might escape via pulmonary shunt. A subclinical high TRPG is an important marker for predicting a worse survival after LDLT, possibly reflecting congestive pressure to the grafted small liver.

    DOI: 10.1186/s12876-018-0793-z

    PubMed

    researchmap

  • Transcatheter Arterial Chemoembolization to Reduce Size of Hepatocellular Carcinoma before Radiofrequency Ablation.

    Soichiro Ako, Shinichiro Nakamura, Kazuhiro Nouso, Chihiro Dohi, Nozomu Wada, Yuki Morimoto, Yasuto Takeuchi, Tetsuya Yasunaka, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    Acta medica Okayama   72 ( 1 )   47 - 52   2018年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for the treatment of early-stage hepatocellular carcinoma (HCC). TACE prior to RFA can expand the ablated area and reduce the tumor size, facilitating complete ablation. However, the factors correlated with size reduction remain uncertain. The aim of this study was to identify the factors associated with size reduction by TACE and develop a formula to predict the reduction rate. A total of 100 HCC patients treated with TACE followed by RFA at least 20 days later were enrolled. The tumor size was measured at the time of TACE and RFA, and correlations between the reduction rate and 13 clinical factors were examined. A formula to predict the reduction rate was built using the factors obtained by the analysis. Reduction in the tumor size was observed in 69 nodules, and the median reduction rate was 16.2%. A multivariate regression analysis revealed that a large tumor size (p< 0.01) and a long interval between the therapies (p= 0.01) were factors for a high tumor reduction rate, with tumor size more strongly related to the degree of reduction. A size reduction of more than 10% can be expected by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter. The tumor size.

    DOI: 10.18926/AMO/55662

    PubMed

    researchmap

  • 肝移植後C型肝炎再発に対するソホスブビル含有治療の有効性

    大山 淳史, 高木 章乃夫, 安中 哲也, 足立 卓哉, 池田 房雄, 和田 望, 竹内 康人, 大西 秀樹, 中村 進一郎, 白羽 英則, 高木 弘誠, 杭瀬 崇, 信岡 大輔, 吉田 龍一, 楳田 祐三, 吉田 真理, 有森 千聖, 八木 孝仁, 岡田 裕之

    肝臓   58 ( 11 )   599 - 604   2017年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    肝移植後C型肝炎に対するDirect Acting Antivirals(DAA)治療効果を検討した。Genotypelは29症例で、ダクラタスビル+アスナプレビル(DCV+ASV)5例、ソホスブビル+レジパスビル(SOF+LDV)25例(含DCV+ASV無効1例)、Genotype2が2症例でSOF+リバビリン治療を行った。DCV+ASVは5例中4例で治療完遂、3例でSustained viral response(SVR)24を達成。SOF+LDVは全例SVR24を達成、移植後2ヵ月以内の肝炎再燃例も含まれているが問題なく治療完遂可能であった。Genotype2はSVR24を達成。SOF中心レジメンで100%のSVR24達成率であり、移植後早期においても問題なくウイルス駆除達成可能であった。C型肝硬変の肝移植適応評価においてC型肝炎のネガティブインパクトはなくなったと言っても過言ではない。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J00263&link_issn=&doc_id=20171128110001&doc_link_id=10.2957%2Fkanzo.58.599&url=https%3A%2F%2Fdoi.org%2F10.2957%2Fkanzo.58.599&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma. 国際誌

    Hiroaki Sawahara, Hidenori Shiraha, Daisuke Uchida, Hironari Kato, Ryo Kato, Atsushi Oyama, Teruya Nagahara, Masaya Iwamuro, Shigeru Horiguchi, Koichiro Tsutsumi, Mari Mandai, Tetsushige Mimura, Nozomu Wada, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Masami Watanabe, Masakiyo Sakaguchi, Akinobu Takaki, Kazuhiro Nouso, Takahito Yagi, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Okada

    Journal of gastroenterology and hepatology   32 ( 10 )   1769 - 1777   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Reduced expression in immortalized cells (REIC)/dickkopf-3 (Dkk-3) is a tumor suppressor gene that is downregulated in various cancers. In our previous study of prostate cancer, the REIC/Dkk-3-expressing adenoviral vector (Ad-REIC) was found to induce cancer-selective apoptosis. This study recently developed a novel super gene expression (SGE) system and used this system to re-construct an Ad-REIC vector, termed the Ad-SGE-REIC, to achieve more effective therapeutic outcomes. In this study, the therapeutic effects of Ad-SGE-REIC on hepatocellular carcinoma (HCC) was assessed. METHODS: Human HCC cell lines (HLE, Huh7, HepG2, HLF, SK-Hep1, and PLC), human HCC tissues, and mouse HCC cell line (Hepa1-6) were used in this study. REIC/Dkk-3 expression was assessed by immunoblotting and immunohistochemistry. The relative cell viability and the apoptotic effect were examined in vitro, and the anti-tumor effects of Ad-SGE-REIC treatment were analyzed in the mouse xenograft model. This study additionally assessed anti-tumor immunological effects on the immunocompetent mice. RESULTS: REIC/Dkk-3 expression was decreased in HCC cell lines and HCC tissues. Ad-SGE-REIC reduced cell viability and induced apoptosis in HCC cell lines (HLE and Huh7), inhibited tumor growth in the mouse xenograft model, and demonstrated in vivo anti-cancer immunostimulatory effects on the HCC cell line (Hepa1-6). CONCLUSIONS: Ad-SGE-REIC treatment not only enhanced cell killing effects in vitro but also elicited significant therapeutic effects, with tumor growth suppression, in vivo. REIC/Dkk-3 gene therapy using Ad-SGE-REIC potentially represents an innovative new therapeutic tool for HCC.

    DOI: 10.1111/jgh.13757

    PubMed

    researchmap

  • 肝炎ウイルス検査陽性患者に対する検査報告システムの効果的な運用方法 肝臓専門医受診率向上のさらなる工夫

    下村 泰之, 藤井 洋輔, 池田 房雄, 安中 哲也, 山崎 典子, 笠原 郁子, 犬山 奈穂美, 小山 道弘, 難波 志穂子, 竹内 康人, 和田 望, 桑木 健志, 大西 秀樹, 中村 進一郎, 白羽 英則, 高木 章乃夫, 岡田 裕之

    肝臓   58 ( 8 )   427 - 434   2017年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    非肝臓専門診療科で実施される肝炎ウイルス検査の結果が受検者に適切に説明されるように、当院では2013年に電子カルテ上で検査陽性を知らせるアラートの自動表示システムを導入した。このシステムを利用して担当医が説明した割合は28%と不十分であったため、検査実施診療科了解のもと検査陽性者へ検査報告書を郵送し、検査陽性者への報告率は89%と改善した。肝臓専門医への紹介状と返信用書類を同封、郵送半年後に肝臓専門医受診を確認できていない場合は再送し、肝炎専門医受診把握率は49%から72%に改善した(p<0.001)。検査報告書再送で肝精査の必要性に気づき肝臓専門医を受診し、肝炎治療を受けた症例もあった。肝炎ウイルス検査陽性者への報告を徹底することは肝臓専門医受診率の向上や適切な肝炎治療の受療に有用である。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J00263&link_issn=&doc_id=20170830080001&doc_link_id=10.2957%2Fkanzo.58.427&url=https%3A%2F%2Fdoi.org%2F10.2957%2Fkanzo.58.427&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 職域での出張肝臓病教室と同時開催の肝炎検診の意義

    難波 志穂子, 池田 房雄, 下村 泰之, 犬山 奈穂美, 大久保 進之介, 槇田 崇志, 長谷川 祐子, 岩井 賢司, 細羽 章子, 三浦 留美, 藤井 洋輔, 安中 哲也, 竹内 康人, 和田 望, 桑木 健志, 大西 秀樹, 中村 進一郎, 白羽 英則, 高木 章乃夫, 岡田 裕之

    肝臓   58 ( 5 )   304 - 306   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    出張肝臓病教室では、岡山大学病院の肝疾患サポートチームが職域に出向き、職員全員を対象として肝炎検診受検や肝臓専門機関受診の重要性を説明した。12回の出張肝臓病教室を603人が受講し、アンケート回答に欠損のない565人の回答を分析した。肝臓病で通院中の人は3人(0.5%)、健康診断で今まで肝機能異常を指摘されたことがない人が468人(82.8%)、健康診断で肝臓に関する検査結果を意識してみていない人が263人(46.5%)であった。肝臓病教室を受講して肝炎ウイルス検査を受けようと思った人が300人(53.1%)、既に受けている人が154人(27.3%)で、111人(19.6%)は受けないと回答した。講演が職場の肝臓病に対する偏見や誤解の解消に非常に役立つと思った人が347人(61.4%)、少し役に立つと思った人が208人(36.8%)であった。出張肝臓病教室に参加した306名中288名(94.1%)が肝炎検診を受検し、HBs抗原陽性者3名(1%)、HCV抗体陽性者3名(1%)であった。陽性者6名全員が肝炎専門医療機関を受診した。

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J00263&link_issn=&doc_id=20170601230005&doc_link_id=10.2957%2Fkanzo.58.304&url=https%3A%2F%2Fdoi.org%2F10.2957%2Fkanzo.58.304&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma. 国際誌

    Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Ayano Oonishi, Akiko Wakuta, Atsushi Oyama, Soichiro Ako, Chihiro Dohi, Nozomu Wada, Yuki Morimoto, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    Journal of gastroenterology and hepatology   32 ( 3 )   695 - 700   2017年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Transcatheter arterial chemoembolization (TACE) is a standard therapy for the treatment of intermediate-stage hepatocellular carcinoma (HCC). In this study, we tried to elucidate the possibility of using radiofrequency ablation (RFA) as an alternative treatment of intermediate-stage HCC. METHODS: Among 246 patients who were initially diagnosed with intermediate-stage HCC, 76 who were treated with TACE (TACE group) and 91 who were treated with RFA (RFA group) were enrolled in this study. The risk for survival was analyzed with the Cox Proportional Hazard Model, and the survival rates were compared using propensity score matching. RESULTS: About half (50.6%) of the intermediate-stage HCC patients in the RFA group were diagnosed with Barcelona Clinic Liver Cancer substage-B1 (BCLC-B1) compared with only 19.7% of the patients in the TACE group. Survival of the RFA group was longer than that of TACE group in patients with BCLC-B1 and BCLC-B2. In contrast, no difference between groups was observed in patients with BCLC-B3/4. Multivariate analysis revealed that large tumor size (>30 mm, hazard ratio = 1.685, P = 0.043), high des-γ-carboxyprothrombin (>100 mAU/mL, hazard ratio = 1.920, P = 0.012), and TACE group (hazard ratio = 1.896, P = 0.016) were significant risk factors for survival. Overall 3-year survival of the patients in the RFA group (69.5%) was significantly longer than that of patients in the TACE group (51.5%) after propensity score matching (P = 0.032). No significant adverse events were observed in either group. CONCLUSIONS: RFA was useful for the treatment of less advanced intermediate-stage HCC and could be an alternative to TACE in selected cases.

    DOI: 10.1111/jgh.13586

    PubMed

    researchmap

  • [Corrigendum] Loss of Runt‑related transcription factor 3 induces resistance to 5‑fluorouracil and cisplatin in hepatocellular carcinoma. 国際誌

    Junro Kataoka, Hidenori Shiraha, Shigeru Horiguchi, Hiroaki Sawahara, Daisuke Uchida, Teruya Nagahara, Masaya Iwamuro, Hiroki Morimoto, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Akinobu Takaki, Kazuhiro Nouso, Takahito Yagi, Kazuhide Yamamoto, Hiroyuki Okada

    Oncology reports   37 ( 3 )   1921 - 1921   2017年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Following the publication of this article, we realize that there were some errors in the manuscript. Details of the experiments describing the gene silencing of RUNX3 with small interfering RNA (siRNA) were erroneously included in this paper, and all references to siRNA should have been deleted from the manuscript prior to publication. In the subsection entitled 'Cell lines and cell culture' on page 2577, the left‑hand column, the text should have indicated that the human HCC cell lines Hep3B and Huh7 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA), whereas HLF cells were obtained from the Japanese Cancer Resources Bank (Tokyo, Japan). Lastly, an error was made in describing the calculation of the IC50 values, which did not correlate with the data shown in Fig. 2. Therefore, the subsection entitled 'Ectopic RUNX3 protein expression suppresses cell growth...' should have been entitled 'Ectopic RUNX3 protein expression increases 5‑FU and CDDP sensitivity', and the text herein should have read as follows: We analyzed the effects of RUNX3 on chemosensitivity in the RUNX3‑ or CAT (mock)‑transfected Hep3B and Huh7 cells. RUNX3 expression enhanced 5‑FU sensitivity in both cell lines; the cell viability with 5‑FU (100 nM) decreased from 66.3±4.6 to 34.3±5.0%, and from 71.0±4.7% to 27.0±5.5% in the Hep3B and Huh7 cells, respectively (Fig. 2A). RUNX3 expression also enhanced CDDP sensitivity in both cell lines; the cell viability with CDDP (100 nM) decreased from 58.7±2.6% to 25.7±4.9%, and from 67.7±4.1% to 25.7±7.5% in the Hep3B and Huh7 cells, respectively (Fig. 2B). We sincerely apologize for these errors and oversights, which have not affected any of the overall conclusions reported in the study, and regret any inconvenience they may have caused. [the original article was published in the Oncology Reports 35: 2576-2582, 2016; DOI: 10.3892/or.2016.4681].

    DOI: 10.3892/or.2017.5419

    PubMed

    researchmap

  • The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.

    Yasuyuki Shimomura, Akinobu Takaki, Nozomu Wada, Tetsuya Yasunaka, Fusao Ikeda, Takayuki Maruyama, Naofumi Tamaki, Daisuke Uchida, Hideki Onishi, Kenji Kuwaki, Shinichiro Nakamura, Kazuhiro Nouso, Yasuhiro Miyake, Kazuko Koike, Takaaki Tomofuji, Manabu Morita, Kazuhide Yamamoto, Hiroyuki Okada

    Internal medicine (Tokyo, Japan)   56 ( 3 )   243 - 251   2017年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Objective Oxidative stress is associated with the progression of chronic liver disease. Non-alcoholic fatty liver disease (NAFLD) is also an oxidative stress-related disease. However, the oxidative/anti-oxidative balance has not been fully characterized in NAFLD. The objective of the present study was to investigate the balance between oxidative stress and the anti-oxidative activity in NAFLD, including non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC). Patients We recruited 69 patients with histologically proven NAFLD without HCC (NAFLD; n=58), and with NASH-related HCC (NASH-HCC; n=11). The 58 NAFLD patients included patients with non-alcoholic fatty liver (NAFL; n=14) and NASH (n=44). Methods The serum levels of reactive oxygen metabolites (ROM) and anti-oxidative markers (OXY) were determined and then used to calculate the oxidative index. The correlations among such factors as ROM, OXY, oxidative index, and clinical characteristics were investigated. Results In NAFLD, ROM positively correlated with the body mass index (BMI), hemoglobin A1c (HbA1c), C-reactive protein (CRP), and the histological grade or inflammatory scores, while only high HbA1c and CRP levels were significant factors that correlated with a higher ROM according to a multivariate analysis. OXY positively correlated with the platelet counts, albumin, and creatinine levels, while negatively correlating with age. However, it improved after treatment intervention. The oxidative index positively correlated with BMI, CRP, and HbA1c. The NASH-HCC patients exhibited a lower OXY than the NASH patients, probably due to the effects of aging. Conclusion Oxidative stress correlated with the levels of NASH activity markers, while the anti-oxidative function was preserved in younger patients as well as in patients with a well-preserved liver function. The NASH-HCC patients tended to be older and exhibited a diminished anti-oxidative function.

    DOI: 10.2169/internalmedicine.56.7002

    PubMed

    researchmap

  • Low-dose FP療法が奏効した切除不能混合型肝癌の1例

    加藤 小百合, 竹内 康人, 和田 望, 森元 裕貴, 桑木 健志, 大西 秀樹, 中村 進一郎, 白羽 英則, 高木 章乃夫, 岡田 裕之

    日本消化器病学会雑誌   113 ( 12 )   2050 - 2056   2016年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    症例は50歳代、女性。肝左葉を占める、肝内多発転移・門脈腫瘍塞栓をともなう混合型肝癌と診断された。肝細胞癌成分が有意と判断し、肝細胞癌に準じた化学療法を導入した。Sorafenib・CDDP肝動注療法では病勢と全身状態の悪化を認めたが、Low-dose FP(LFP)療法は奏効を認め、長期生存が得られている。今回LFP療法が、切除不能な混合型肝癌の治療の選択肢としても有効である可能性が示唆された。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J01118&link_issn=&doc_id=20161222160009&doc_link_id=130005179285&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130005179285&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  • Potential of alpha-fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma. 国際誌

    Chihiro Dohi, Kazuhiro Nouso, Koji Miyahara, Yuki Morimoto, Nozomu Wada, Hideaki Kinugasa, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    Hepatology research : the official journal of the Japan Society of Hepatology   46 ( 9 )   916 - 23   2016年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Recurrence of hepatocellular carcinoma (HCC) is observed frequently, even after curative treatments. The aim of this study is to elucidate the risk factors for recurrence of HCC after radiofrequency ablation (RFA), focusing on the carcinogenic potential of the liver assessed by α-fetoprotein (AFP). METHODS: We enrolled 357 consecutive patients who underwent complete ablation by RFA for primary HCC (≤3 cm, ≤3 tumors) and analyzed the correlation between 17 critical parameters, including AFP and HCC recurrence. RESULTS: Recurrence was observed in 236 patients during a mean observation period of 54.3 months. Multivariate analysis revealed that multiple tumors (risk ratio [RR] = 1.70, 95% confidence interval [CI] = 1.27-2.26, P < 0.001), high AFP (>10 ng/mL, RR = 1.45, 95% CI = 1.09-1.94, P < 0.001) and high des-γ-carboxyprothrombin (>40 mAU/mL, RR = 1.52, 95% CI = 1.13-2.02, P < 0.005) were significantly correlated with recurrence. AFP was selected as a significant factor even when the cut-off level was set lower (≤5 ng/mL). The risk of recurrence increased linearly according to the increase of the lowest AFP level after RFA and the adjusted ratios relative to AFP less than 5 ng/mL were 1.56, 2.14, 2.57 and 3.13 in AFP 5-10 ng/mL, 10-20 ng/mL, 20-50 ng/mL and over 50 ng/mL, respectively. In addition, the recurrence rate was predicted by the AFP level after RFA, regardless of the level before the treatment. CONCLUSION: AFP less than 5 ng/mL after curative RFA was an important predictor of a better prognosis and was considered to indicate the low carcinogenic potential of the non-cancerous liver.

    DOI: 10.1111/hepr.12636

    PubMed

    researchmap

  • Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma. 国際誌

    Junro Kataoka, Hidenori Shiraha, Shigeru Horiguchi, Hiroaki Sawahara, Daisuke Uchida, Teruya Nagahara, Masaya Iwamuro, Hiroki Morimoto, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Akinobu Takaki, Kazuhiro Nouso, Takahito Yagi, Kazuhide Yamamoto, Hiroyuki Okada

    Oncology reports   35 ( 5 )   2576 - 82   2016年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Runt-related transcription factor 3 (RUNX3) is known to function as a tumor suppressor in gastric cancer and other types of cancers, including hepatocellular carcinoma (HCC). However, its role has not been fully elucidated. In the present study, we aimed to evaluate the role of RUNX3 in HCC. We used the human HCC cell lines Hep3B, Huh7 and HLF; RUNX3 cDNA was introduced into Hep3B and Huh7 cells, which were negative for endogenous RUNX3 expression, and RUNX3 siRNA was transfected into HLF cells, which were positive for endogenous RUNX3. We analyzed the expression of RUNX3 and multidrug resistance-associated protein (MRP) by immunoblotting. MTT assays were used to determine the effects of RUNX3 expression on 5-fluorouracil (5-FU) and cisplatin (CDDP) sensitivity. Finally, 23 HCC specimens resected from patients with HCC at Okayama University Hospital were analyzed, and correlations among immunohistochemical expression of RUNX3 protein and MRP protein were evaluated in these specimens. Exogenous RUNX3 expression reduced the expression of MRP1, MRP2, MRP3 and MRP5 in the RUNX3-negative cells, whereas knockdown of RUNX3 in the HLF cells stimulated the expression of these MRPs. An inverse correlation between RUNX3 and MRP expression was observed in the HCC tissues. Importantly, loss of RUNX3 expression contributed to 5-FU and CDDP resistance by inducing MRP expression. These data have important implications in the study of chemotherapy resistance in HCC.

    DOI: 10.3892/or.2016.4681

    PubMed

    researchmap

  • Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C. 国際誌

    Shintaro Nanba, Fusao Ikeda, Nobuyuki Baba, Koichi Takaguchi, Tomonori Senoh, Takuya Nagano, Hiroyuki Seki, Yasuto Takeuchi, Yuki Moritou, Tetsuya Yasunaka, Hideki Ohnishi, Yasuhiro Miyake, Akinobu Takaki, Kazuhiro Nouso, Yoshiaki Iwasaki, Kazuhide Yamamoto

    Journal of clinical pathology   69 ( 3 )   226 - 33   2016年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Oxidative stress may play pathogenic roles in the mechanisms underlying chronic hepatitis C (CHC). The impact of excessive oxidative stress and iron dysregulation on the development of hepatocellular carcinoma (HCC) after interferon therapy has not been established. METHODS: We investigated the impact of oxidative stress and iron deposition on HCC development after therapy with pegylated interferon (PegIFN)+ribavirin in CHC patients. Systemic and intracellular iron homeostasis was evaluated in liver tissues, peripheral blood mononuclear cells and sera. RESULTS: Of 203 patients enrolled, 13 developed HCC during the 5.6-year follow-up. High hepatic 8-hydroxy-2-deoxyguanosine (8-OHdG) levels were significantly associated with HCC development in multivariate analysis (p=0.0012) which was also significantly correlated with severity of hepatic iron deposition before therapy (p<0.0001). Systemic and intracellular iron regulators of hepcidin and F-box and leucine-rich repeat protein 5 (FBXL5) expression levels were significantly suppressed in CHC patients (p=0.0032 and p=0.016, respectively) despite their significantly higher levels of serum iron and ferritin compared with controls. However, intracellular iron regulators of FBXL5 and iron regulatory proteins were regulated in balance with hepatic iron deposition. Significant correlations were observed among IL-6, bone morphogenetic protein 6, hepcidin and ferroportin, as regards systemic iron regulation. CONCLUSIONS: Measurement of hepatic oxidative stress before antiviral therapy is useful for the prediction of HCC development after interferon therapy. Low baseline levels of the intracellular iron regulators of FBXL5 in addition to a suppressed hepcidin level might be associated with severe hepatic iron deposition in CHC patients. TRIAL REGISTRATION NUMBER: UMIN 000001031.

    DOI: 10.1136/jclinpath-2015-203215

    PubMed

    researchmap

  • A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy.

    Sayuri Kato, Yasuto Takeuchi, Nozomu Wada, Yuuki Morimoto, Kenji Kuwaki, Hideki Ohnishi, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology   113 ( 12 )   2050 - 2056   2016年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A woman in her 50s was admitted to our hospital because of multiple tumors detected in her liver. She was diagnosed with combined hepatocellular cholangiocarcinoma using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) and biopsy of the liver tumors. We judged the tumors to be unresectable because they were found in both lobes of the liver, with a tumor thrombus being found in the main left portal vein. The pathological findings showed that the tumors exhibited characteristics of hepatocellular carcinoma. Therefore, sorafenib was administered;however, 6 months later, the disease progressed. Consequently, she received second-line chemotherapy with a one-shot intra-arterial injection of cisplatin, but this too was ineffective, and her general condition worsened. As hence, we changed the regimen to 5-fluorouracil continuous infusion and consecutive low dose cisplatin (LFP) therapy. After one cycle of chemotherapy with LFP, Gd-EOB-DTPA-enhanced MRI showed markedly decreased sizes and numbers of tumors. To date, she has completed six cycles of LFP therapy, and almost all her tumors are no longer visible on MRI. She has recovered to a good state and has achieved long-term survival. Thus, this case indicates that although LFP therapy is generally selected for cases of advanced hepatocellular carcinoma, it also appears to be effective for long-term disease control in cases of hepatocellular cholangiocarcinoma.

    PubMed

    researchmap

  • Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. 国際誌

    Yasuto Takeuchi, Fusao Ikeda, Toshiya Osawa, Yasuyuki Araki, Kouichi Takaguchi, Youichi Morimoto, Noriaki Hashimoto, Kousaku Sakaguchi, Tatsuro Sakata, Masaharu Ando, Yasuhiro Makino, Shuji Matsumura, Hiroki Takayama, Hiroyuki Seki, Shintarou Nanba, Yuki Moritou, Tetsuya Yasunaka, Hideki Ohnishi, Akinobu Takaki, Kazuhiro Nouso, Yoshiaki Iwasaki, Kazuhide Yamamoto

    World journal of hepatology   7 ( 19 )   2220 - 8   2015年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: To investigate factors that accurately predict hepatocellular carcinoma (HCC) development after antiviral therapy in chronic hepatitis C (CHC) patients. METHODS: CHC patients who received pegylated interferon and ribavirin were enrolled in this cohort study that investigated the ability of alpha-fetoprotein (AFP) to predict HCC development after interferon (IFN) therapy. RESULTS: Of 1255 patients enrolled, 665 developed sustained virological response (SVR) during mean follow-up period of 5.4 years. HCC was occurred in 89 patients, and 20 SVR patients were included. Proportional hazard models showed that HCC occurred in SVR patients showing AFP ≥ 5 ng/mL before therapy and in non-SVR patients showing AFP ≥ 5 ng/mL before and 1 year after therapy besides older age, and low platelet counts. SVR patients showing AFP ≥ 5 ng/mL before therapy and no decrease in AFP to < 5 ng/mL 1 year after therapy had significantly higher HCC incidence than non-SVR patients showing AFP ≥ 5 ng/mL before therapy and decreased AFP (P = 0.043). AFP ≥ 5 ng/mL before therapy was significantly associated with low platelet counts and high values of alanine aminotransferase (ALT) in stepwise logistic regression analysis. After age, gender, platelet count, and ALT was matched by propensity score, significantly lower HCC incidence was shown in SVR patients showing AFP < 5 ng/mL before therapy than in those showing AFP ≥ 5 ng/mL. CONCLUSION: The criteria of AFP < 5 ng/mL before and 1 year after IFN therapy is a benefical predictor for HCC development in CHC patients.

    DOI: 10.4254/wjh.v7.i19.2220

    PubMed

    researchmap

  • Alteration of N-glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma. 国際誌

    Koji Miyahara, Kazuhiro Nouso, Chihiro Dohi, Yuki Morimoto, Hideaki Kinugasa, Nozomu Wada, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Maho Amano, Shin-Ichiro Nishimura, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   45 ( 9 )   986 - 993   2015年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Most of the modification of N-glycosylation reported in cancers including hepatocellular carcinoma (HCC) were based on the examinations of a small number of patients or particular proteins. The aim of this study is to reveal changes in whole serum N-glycan profiles systematically during the process of hepatocarcinogenesis and to elucidate their clinical application. METHODS: We analyzed sera from 105 patients with chronic hepatitis/liver cirrhosis (CH/LC) and age-/sex-matched healthy volunteers (HLT), as well as from 114 patients with HCC. Serum N-glycan profiles were measured comprehensively by a new, quantitative, high-throughput method and compared with clinical parameters. RESULTS: The total amount of N-glycan expression was significantly higher in patients with CH/LC than in HLT; however, no differences were observed between CH/LC and HCC patients. In HCC patients, multi-antennary glycans with fucose residues, particularly m/z 3195, were increased compared with CH/LC patients. The expression of m/z 3195 was high, especially in patients with a high number of intrahepatic lesions (>3), large tumor size (>3 cm), macroscopic vascular invasion or metastasis. The ratio of pairs of glycans on the same path of the biosynthesis pathway (m/z 3195/1914) showed a higher area under the receiver-operator curve of 0.810 than any other single glycan to distinguish HCC from CH/LC. CONCLUSION: We demonstrate the full spectrum of the alterations of serum N-glycans comprehensively in patients with liver disease, and elucidate the possible use of glycans as novel biomarkers of liver disease progression.

    DOI: 10.1111/hepr.12441

    PubMed

    researchmap

  • Hepatic stellate cells promote upregulation of epithelial cell adhesion molecule and epithelial-mesenchymal transition in hepatic cancer cells. 国際誌

    Teruya Nagahara, Hidenori Shiraha, Hiroaki Sawahara, Daisuke Uchida, Yasuto Takeuchi, Masaya Iwamuro, Junro Kataoka, Shigeru Horiguchi, Takeshi Kuwaki, Hideki Onishi, Shinichiro Nakamura, Akinobu Takaki, Kazuhiro Nouso, Kazuhide Yamamoto

    Oncology reports   34 ( 3 )   1169 - 77   2015年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Microenvironment plays an important role in epithelial-mesenchymal transition (EMT) and stemness of cells in hepatocellular carcinoma (HCC). Epithelial cell adhesion molecule (EpCAM) is known as a tumor stemness marker of HCC. To investigate the relationship between microenvironment and stemness, we performed an in vitro co-culture assay. Four HCC cell lines (HepG2, Hep3B, HuH-7 and PLC/PRF/5) were co-cultured with the TWNT-1 immortalized hepatic stellate cells (HSCs), which create a microenvironment with HCC. Cell proliferation ability was analyzed by flow cytometry (FCM) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, while migration ability was assessed by a wound healing assay. Expression of EpCAM was analyzed by immunoblotting and FCM. HCC cell lines were co-cultured with TWNT-1 treated with small interfering RNA (siRNA) for TGF-β and HB-EGF; we then analyzed proliferation, migration ability and protein expression using the methods described above. Proliferation ability was unchanged in HCC cell lines co-cultured with TWNT-1. Migration ability was increased in HCC cell lines (HepG2, Hep3B, HuH-7 and PLC/PRF/5) directly (216.2±67.0, 61.0±22.0, 124.0±66.2 and 51.5±40.3%) and indirectly (102.5±22.0, 84.6±30.9, 86.1±25.7 and 73.9±29.7%) co-cultured with TWNT-1 compared with the HCC uni-culture. Immunoblot analysis revealed increased EpCAM expression in the HCC cell lines co-cultured with TWNT-1. Flow cytometry revealed that the population of E-cadherin-/N-cadherin+ and EpCAM-positive cells increased and accordingly, EMT and stemness in the HCC cell line were activated. These results were similar in the directly and indirectly co-cultured samples, indicating that humoral factors were at play. Conversely, HCC cell lines co-cultured with siRNA‑treated TWNT-1 showed decreased migration ability, a decreased population of EpCAM-positive and E-cadherin-/N-cadherin+ cells. Taken together, humoral factors secreted from TWNT-1 promote upregulation of EpCAM and EMT in hepatic cancer cells.

    DOI: 10.3892/or.2015.4126

    PubMed

    researchmap

  • Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine. 国際誌

    Koji Miyahara, Kazuhiro Nouso, Yuki Morimoto, Hideaki Kinugasa, Hironari Kato, Naoki Yamamoto, Koichiro Tsutsumi, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Taku Nakahara, Yoshiaki Miura, Hidehisa Asada, Maho Amano, Shin-Ichiro Nishimura, Kazuhide Yamamoto

    Pancreas   44 ( 4 )   551 - 6   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: The objectives of this study were to examine the whole-serum N-glycan profile of patients with unresectable pancreatic cancer and to evaluate the ability of glycans to predict gemcitabine treatment efficacy and patient survival. METHODS: We collected serum from 52 patients with advanced pancreatic cancer before they began gemcitabine monotherapy. The serum glycan profile was measured through comprehensive quantitative high-throughput glycome analysis and compared with the treatment efficacy and patient survival. RESULTS: Of the 61 glycans detected, the serum levels of glycan 4310 (molecular weight [m/z] 1549.566), 6301 (m/z 2032.724), and 9200 (m/z 2010.692) were high in patients with a short time to tumor progression (TTP). Multivariate analysis revealed that a high glycan 9200 concentration was an independent risk factor for shorter TTP (hazard ratio, 2.11; 95% confidence interval, 1.07-4.17) and poor overall survival (hazard ratio, 2.56; 95% confidence interval, 1.08-6.19). The median TTP of patients with up-regulation of 9200 after gemcitabine treatment was shorter than for the remaining patients (91 vs 301 days; P = 0.0005). A similar relationship was observed for overall survival (median, 181 vs 561 days; P = 0.001). CONCLUSIONS: Glycan 9200 is a possible biomarker predicting gemcitabine efficacy survival in patients with unresectable pancreatic cancer.

    DOI: 10.1097/MPA.0000000000000321

    PubMed

    researchmap

  • Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis. 国際誌

    Yasushi Yamasaki, Kazuhiro Nouso, Koji Miyahara, Nozomu Wada, Chihiro Dohi, Yuki Morimoto, Hideaki Kinugasa, Yasuto Takeuchi, Tetsuya Yasunaka, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Yoshiaki Iwasaki, Maho Amano, Shin-Ichiro Nishimura, Kazuhide Yamamoto

    Journal of gastroenterology and hepatology   30 ( 3 )   528 - 34   2015年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non-alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non-alcoholic steatohepatitis (NASH) from simple steatosis (SS). METHODS: We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high-throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined. RESULTS: Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis. CONCLUSION: We clearly demonstrated whole-serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.

    DOI: 10.1111/jgh.12726

    PubMed

    researchmap

  • Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. 国際誌

    Hideki Onishi, Kazuhiro Nouso, Shinichiro Nakamura, Kuniaki Katsui, Nozomu Wada, Yuki Morimoto, Koji Miyahara, Yasuto Takeuchi, Kenji Kuwaki, Tetsuya Yasunaka, Yasuhiro Miyake, Hidenori Shiraha, Akinobu Takaki, Yoshiyuki Kobayashi, Kohsaku Sakaguchi, Susumu Kanazawa, Kazuhide Yamamoto

    Hepatology international   9 ( 1 )   105 - 12   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The presence of portal vein tumor thrombosis (PVTT) is a poor prognostic factor for patients with hepatocellular carcinomas (HCC). The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients. METHODS: We retrospectively examined the outcome of 67 HCC patients with PVTT of the main trunk or first branch who received HAIC alone or with concurrent irradiation for PVTT (CCRT). RESULTS: Thirty-four patients received HAIC, and 33 patients received CCRT. The time to progression (TTP) of PVTT in the CCRT group was significantly longer than in the HAIC group (p < 0.01), and the TTP of intrahepatic nodules in the CCRT group tended to be longer than in the HAIC group (p = 0.06). The objective response rates of intrahepatic nodules (52 vs. 18%, p < 0.01) and PVTT (45 vs. 18%, p = 0.01) were both significantly higher in the CCRT group than in the HAIC group, respectively. No significant difference in overall survival was found between the two groups (p = 0.14); however, the median survival time in the CCRT group was longer than that in the HAIC group (12.4 vs. 5.7 months, respectively). CONCLUSIONS: CCRT might be a promising treatment for advanced-stage HCC with PVTT. CCRT prolonged the TTP of intrahepatic nodules and PVTT, and it improved the objective response rate of intrahepatic nodules and PVTT.

    DOI: 10.1007/s12072-014-9592-y

    PubMed

    researchmap

  • Aberrant Expression of Keratin 7 in Hepatocytes as a Predictive Marker of Rapid Progression to Hepatic Failure in Asymptomatic Primary Biliary Cirrhosis.

    Hiroyuki Seki, Fusao Ikeda, Shintaro Nanba, Yuki Moritou, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Onishi, Yasuhiro Miyake, Akinobu Takaki, Kazuhiro Nouso, Yoshiaki Iwasaki, Minoru Nakamura, Kazuhide Yamamoto

    Acta medica Okayama   69 ( 3 )   137 - 44   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A predictive marker of the rapid progression to hepatic failure is desired for patients with asymptomatic primary biliary cirrhosis (aPBC). We performed a systematic cohort analysis of 101 patients diagnosed as having aPBC and the rapid progression to liver failure in some, by focusing on cholestasis. Cholestasis was assessed by aberrant keratin7 (K-7) expressions in the patients' hepatocytes. Intralobular expressions of K-7 were found in 9 of the 101 patients. The grades of K-7 expression were significantly associated with the levels of alanine aminotransferase, alkaline phosphatase, and total bilirubin at the time of diagnosis, but not with bile duct loss or cholestasis. Stepwise logistic regression analysis revealed that high grades of K-7 expression correlated positively with high levels of total bilirubin. During the follow-up period, 8 patients developed jaundice, and the mean period until the development of jaundice was 5.2 years. The proportional hazards models for the risk of developing jaundice identified a high grade of aberrant K-7 expression in hepatocytes as the only significant risk factor. Aberrant K-7 expression in hepatocytes can be used as an additional marker to predict rapid progression to liver failure in patients with aPBC at the time of diagnosis.

    PubMed

    researchmap

  • Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location.

    Junichi Toshimori, Kazuhiro Nouso, Shinichiro Nakamura, Nozomu Wada, Yuki Morimoto, Yasuto Takeuchi, Tetsuya Yasunaka, Kenji Kuwaki, Hideki Ohnishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

    Acta medica Okayama   69 ( 4 )   219 - 26   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We conducted a retrospective cohort study to investigate the predisposing factors for local recurrence and complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). HCC patients (n=397) consecutively treated with RFA (256 males, 141 females, median age 69 years) were enrolled. In these patients, 1,455 nodules (median size 17mm) were ablated. Predisposing factors for overall recurrence and local recurrence in the context of tumor location and complications were examined. Local recurrence was observed for 113 of the 1,455 nodules. The 1-, 3- and 5-year local recurrence rates were 2.2%, 7.4% and 9.5%, respectively. A multivariate Cox proportional hazard analysis revealed that large tumor size (>2cm), tumor location (adjacent to the major portal branch or hepatic vein), and small ablated margin (<3mm) were independent predisposing factors for local recurrence after RFA (HR=1.70-2.81). Tumor location (adjacent to the major portal branch, hepatic vein, or diaphragm) was also revealed as a risk factor for liver damage due to RFA. HCC adjacent to the major portal vein or hepatic vein was associated with a higher risk for local recurrence and for complications;therefore, special precautions are necessary when applying RFA to HCC near vessels even when the tumors are located at an easy-to-puncture site.

    PubMed

    researchmap

  • Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma. 国際誌

    Yuki Morimoto, Kazuhiro Nouso, Nozomu Wada, Yasuto Takeuchi, Hideaki Kinugasa, Koji Miyahara, Tetsuya Yasunaka, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   44 ( 14 )   E353-9   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Recently, a relationship between platelets and cancer metastasis has been reported. The aim of this study is to elucidate the risk factors for extrahepatic metastasis (EHM), with emphasis on association with platelets in patients, with hepatocellular carcinoma (HCC). METHODS: We examined risk factors for EHM in 1613 consecutive, newly diagnosed HCC patients by logistic regression analysis (case-control study). We also examined the factors by Cox proportional hazard model in a retrospective cohort fashion in 803 patients who received non-curative treatment for HCC. RESULTS: In the case-control study, multivariate analysis revealed that high platelet counts (odds ratio [OR] = 4.84; 95% confidence interval [CI] = 1.29-29.54; P = 0.01), high tumor number and the presence of macroscopic vascular invasion were significantly associated with EHM. In the cohort study, EHM was diagnosed in 71 patients during the study period (mean observation time = 23.3 months). On multivariate analysis, high tumor number, high des-γ-carboxyprothrombin (DCP) and Child-Pugh class A were significantly correlated with EHM, and the patients with high platelet counts tended to develop EHM (OR = 1.73; 95% CI = 0.99-3.14; P = 0.055). CONCLUSION: HCC patients with high platelet counts, as well as large numbers of tumors, high serum DCP and Child-Pugh class A, are at risk for EHM.

    DOI: 10.1111/hepr.12315

    PubMed

    researchmap

  • Prevention of vagotonia and pain during radiofrequency ablation of liver tumors. 国際誌

    Shinichiro Nakamura, Kazuhiro Nouso, Hideki Onishi, Kenji Kuwaki, Hiroaki Hagihara, Yasuto Takeuchi, Nozomu Wada, Yuki Morimoto, Koji Miyahara, Tetsuya Yasunaka, Fusao Ikeda, Yasuhiro Miyake, Yoshiyuki Kobayashi, Hidenori Shiraha, Shinichi Ishikawa, Akinobu Takaki, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   44 ( 13 )   1367 - 70   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Radiofrequency ablation (RFA) is frequently used to treat early stage hepatocellular carcinoma. Two of the most cumbersome side-effects of the ablation procedure are intractable pain and vagotonia when deep sedation is not used. We describe local injection of anesthetic into Glisson's sheath as a new technique for overcoming these problems. Lidocaine was injected into Glisson's sheath when radiofrequency ablation of hepatocellular carcinomas, which were located adjacent to Glisson's sheath, could not be continued due to severe pain (n = 8) or bradycardia (n = 3). In all three patients who showed vagotonia with bradycardia during the ablations, injection of lidocaine prevented bradycardia, allowing completion of the radiofrequency ablation. Pain was reduced in all eight patients who experienced pain during ablation. No side-effects were observed during the procedures. Injection of anesthetic into Glisson's sheath is simple and effective for reducing intractable pain and vagotonia associated with RFA.

    DOI: 10.1111/hepr.12321

    PubMed

    researchmap

  • Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. 国際誌

    Koji Miyahara, Kazuhiro Nouso, Yuki Morimoto, Yasuto Takeuchi, Hiroaki Hagihara, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Shouta Iwadou, Yoshiyuki Kobayashi, Koichi Takaguchi, Yoshitaka Takuma, Hiroyuki Takabatake, Kohsaku Sakaguchi, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   44 ( 3 )   296 - 301   2014年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. METHODS: The size of metastatic lesions was measured in 36 patients with advanced HCC treated with sorafenib. The tumor growth rates before and after radiological PD as well as survival were compared between the patients who continued (n = 23) and stopped (n = 13) sorafenib at first radiological PD. RESULTS: The growth rate did not differ between before and after PD in patients who continued sorafenib, while it increased after PD in patients who stopped sorafenib at PD (P = 0.002). Survival beyond first progression was longer in patients who continued sorafenib than in those who stopped it at PD (P = 0.012), and this tendency was observed even when the analysis was limited to Child-Pugh class A patients (P = 0.085). CONCLUSION: Sorafenib administration beyond first radiological PD could continuously suppress HCC growth and may have survival benefit.

    DOI: 10.1111/hepr.12123

    PubMed

    researchmap

  • Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. 国際誌

    Hiroshi Matsushita, Fusao Ikeda, Yoshiaki Iwasaki, Hiroyuki Seki, Shintaro Nanba, Yasuto Takeuchi, Yuki Moritou, Tetsuya Yasunaka, Hideki Onishi, Yasuhiro Miyake, Akinobu Takaki, Kazuhiro Nouso, Kazuhide Yamamoto

    Journal of gastroenterology and hepatology   29 ( 2 )   337 - 43   2014年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Chronic infection with hepatitis C virus (HCV) decreases health-related quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated interferon and ribavirin (RBV), in addition to IL28B polymorphisms. METHODS: The present study enrolled 228 CHC patients and assessed their HRQOLs prospectively with the 36-item short-form health survey. RESULTS: The patients with CHC have lower physical HRQOL status than the general population (P = 0.037, the Z-test). The patients with advanced liver diseases exhibited further decreases in HRQOL (P = 0.036, Spearman's rank correlation coefficient). The score of total HRQOL was significantly lower in the group with sustained virological response (SVR) to the therapy with pegylated interferon and RBV than the non-SVR group (P = 0.031, the Mann-Whitney U-test), with significantly lower scores of mental component and its comprising subscales in the SVR group. Stepwise multivariate logistic regression analysis showed that low HRQOL score ≤ 400 points was significantly associated with SVR (odds ratio = 2.4, P = 0.013), independently from high platelet counts, low HCV RNA, favorable single-nucleotide polymorphism type of IL28B, and HCV serotype 2. The patients with low HRQOL score will have significantly less decrease in HRQOL score by 4 weeks of the treatment than those with high HRQOL score at baseline (P = 0.0045). CONCLUSION: HRQOL is one of the significant predictor of the outcomes of therapy with pegylated interferon and RBV independently from IL28B polymorphism.

    DOI: 10.1111/jgh.12337

    PubMed

    researchmap

  • Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor.

    Yuki Moritou, Fusao Ikeda, Yoshiaki Iwasaki, Nobuyuki Baba, Kouichi Takaguchi, Tomonori Senoh, Takuya Nagano, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Ohnishi, Yasuhiro Miyake, Akinobu Takaki, Kazuhiro Nouso, Kazuhide Yamamoto

    Acta medica Okayama   68 ( 1 )   17 - 22   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The impact of hepatic steatosis on interferon therapy for patients with chronic hepatitis C (CHC) has been associated with single-nucleotide polymorphisms (SNP) of IL28B, patatin-like phospholipase domain-containing protein 3 (PNPLA3), and low-density lipoprotein (LDL) receptor. Whether this holds true for Japanese patients, however, remains unresolved. The present study prospectively enrolled 226 Japanese patients with CHC, and investigated the impact of hepatic steatosis and its related SNPs, including rs8099917 of IL28B, rs738409 of PNPLA3, and rs14158 of LDL receptor, on outcomes of peg-interferon and ribavirin therapy. In multivariate logistic regression analysis, significant factors affecting the severity of hepatic steatosis were high body mass index and the minor alleles of IL28B SNP (p=0.020 and 0.039, respectively). The risk alleles of PNPLA3 SNP also showed weak association (p=0.059). Severe steatosis and the minor alleles of IL28B SNP were significantly associated with null or partial virological response in patients with HCV genotype 1, as were female gender, and low LDL cholesterol (p=0.049, and <0.001, respectively). The SNP genotype of PNPLA3 and LDL receptor did not have a significant impact on therapeutic outcomes. With respect to the SNP sites examined, the SNP of PNPLA3 has a weak association with severe hepatic steatosis, but not with the outcome of interferon therapy.

    PubMed

    researchmap

  • Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C. 国際誌

    Yuki Moritou, Fusao Ikeda, Yoshiaki Iwasaki, Nobuyuki Baba, Kouichi Takaguchi, Tomonori Senoh, Takuya Nagano, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Ohnishi, Yasuhiro Miyake, Akinobu Takaki, Kazuhiro Nouso, Kazuhide Yamamoto

    SpringerPlus   2 ( 1 )   251 - 251   2013年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The impact of single-nucleotide polymorphisms (SNP) of patatin-like phospholipase domain-containing protein 3 (PNPLA3) on development of hepatocellular carcinoma (HCC) is not clarified for Japanese patients with chronic hepatitis C. The present study investigated the associations of rs738409 PNPLA3 with HCC development after the antiviral therapy with peg-interferon and ribavirin for Japanese patients with hepatitis C virus serotype 1 and high viral load. Of the 271 patients enrolled in the study, 20 patients developed HCC, during a median follow-up period of 4.6 years. Multivariate analysis in the proportional hazards models revealed that sex, body mass index, platelet counts, and alpha feroprotein (AFP) had significant associations with HCC development (p = 0.011, 0.029, 0.0002, and 0.046, respectively). Multivariate regression analysis revealed that PNPLA3 148 M was significantly associated with serum AFP level (p = 0.032), other than body mass index, platelet count, and alanine aminotransferase (p = 0.0006, 0.0002, and 0.037, respectively), and that serum AFP level was significantly associated with PNPLA3 148 M (p = 0.017). Serum AFP level is an important factor in predicting HCC development after the antiviral therapy for Japanese patients with chronic hepatitis C, the mechanism of which might involve its significant associations with the SNP genotype of PNPLA3.

    DOI: 10.1186/2193-1801-2-251

    PubMed

    researchmap

  • Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. 国際誌

    Koji Miyahara, Kazuhiro Nouso, Yuki Morimoto, Takeshi Tomoda, Sayo Kobayashi, Yasuto Takeuchi, Hiroaki Hagihara, Kenji Kuwaki, Hideki Ohnishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   43 ( 10 )   1064 - 70   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Des-γ-carboxyprothrombin (DCP) is known to be increased by the use of sorafenib for the treatment of hepatocellular carcinoma (HCC), despite its therapeutic efficacy. In addition to the tumor progression, hypoxia that impairs vitamin K uptake is known to induce DCP and this mechanism may explain DCP elevation by sorafenib. In this study, we tried to evaluate the effect of sorafenib treatment using a new marker, NX-DCP, which is specific to vitamin K absence. METHODS: Serum DCP and NX-DCP were measured in 50 consecutive HCC patients before and 1 week after starting sorafenib, and compared with the treatment effect using the modified Response Evaluation Criteria in Solid Tumors guidelines. RESULTS: DCP and NX-DCP increased 1.58- (median, range 0.21-28.7) and 1.20-fold (median, range 0.41-14.2) after the administration of sorafenib, respectively. The increases of both markers were less than twofold in approximately half of the patients (low-elevation group). However, 12 patients showed over twofold increase of both DCP and NX-DCP (double-elevation group), and eight patients showed over twofold increase of DCP alone (DCP-elevation group). The disease control rate (DCR) of the DCP-elevation group (12.5%) was significantly lower than those of the double-elevation group (75.0%, P = 0.020) and the low-elevation group (60.0%, P = 0.042). Progression-free survival (PFS) was significantly shorter in the DCP-elevation group than in the double-elevation group (P = 0.006) and the low-elevation group (P = 0.001). CONCLUSION: NX-DCP in combination with DCP could be a useful biomarker of sorafenib treatment for advanced HCC.

    DOI: 10.1111/hepr.12055

    PubMed

    researchmap

  • Serum oxidative-anti-oxidative stress balance is dysregulated in patients with hepatitis C virus-related hepatocellular carcinoma. 国際誌

    Mamoru Nishimura, Akinobu Takaki, Naofumi Tamaki, Takayuki Maruyama, Hideki Onishi, Sayo Kobayashi, Kazuhiro Nouso, Tetsuya Yasunaka, Kazuko Koike, Hiroaki Hagihara, Kenji Kuwaki, Shinichiro Nakamura, Fusao Ikeda, Yoshiaki Iwasaki, Takaaki Tomofuji, Manabu Morita, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   43 ( 10 )   1078 - 92   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Oxidative stress is associated with progression of chronic liver disease (CLD). This association is best established in chronic hepatitis C. However, the anti-oxidative state is not well characterized. The objective of the present study was to investigate the balance of oxidative and anti-oxidative stress in CLD patients. METHODS: We recruited a study population of 208 patients, including healthy volunteers (HV; n = 15), patients with hepatitis B virus (HBV)-related CLD without or with hepatocellular carcinoma (HBV-non-HCC, n = 25, and HBV-HCC, n = 50, respectively), and patients with hepatitis C virus (HCV)-related CLD without or with HCC (HCV-non-HCC, n = 49, and HCV-HCC, n = 69, respectively). Serum levels of reactive oxygen metabolites (ROM) and anti-oxidative markers (OXY-adsorbent test; OXY) were determined, and the balance of these values was used as the oxidative index. Correlations among ROM, OXY, oxidative index and clinical characteristics were investigated. RESULTS: Patients with CLD exhibited elevated ROM and oxidative index compared to HV. Among patients with CLD, HCV positive status correlated with increased ROM. In CLD, HCV-HCC patients exhibited the highest ROM levels. Among HCV-related CLD patients, lower OXY correlated with HCC positive status, but was recovered by eradication of HCC. In HCV-HCC, lower OXY correlated with high PT-INR. CONCLUSION: HCV positive CLD patients displayed higher oxidative stress and HCV-HCC patients displayed lower anti-oxidative state. Anti-oxidative state depression was associated with liver reservoir-related data in HCV-HCC and could be reversed with HCC eradication.

    DOI: 10.1111/hepr.12048

    PubMed

    researchmap

  • Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer.

    Kazuhiro Nouso, Maho Amano, Yoichi M Ito, Koji Miyahara, Yuki Morimoto, Hironari Kato, Koichiro Tsutsumi, Takeshi Tomoda, Naoki Yamamoto, Shinichiro Nakamura, Sayo Kobayashi, Kenji Kuwaki, Hiroaki Hagihara, Hideki Onishi, Yasuhiro Miyake, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Taku Nakahara, Shin-Ichiro Nishimura, Kazuhide Yamamoto

    Journal of gastroenterology   48 ( 10 )   1171 - 9   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Most of the glycan changes reported in cancers were based on the examinations of a small number of patients or particular proteins. The aim of this study was to determine the changes of the serum N-glycan profile comprehensively in a large number of pancreatic cancer patients and investigate its clinical utility. METHODS: Glycan levels in the serum of 92 pancreatic cancer patients and 243 healthy volunteers (HLT) were examined by comprehensive quantitative high-throughput glycome analysis and were compared with clinical parameters. RESULTS: Out of 66 glycans detected, 15 were differentially expressed in pancreatic cancer, and 10 out of the 15 glycans were significantly up-regulated in cases with distant metastasis. There was a clear increase in overall expression of serum glycans, especially highly-branched glycans with fucose moieties, in pancreatic cancer. Among these 15 glycans, a tri-antennary complex type glycan (m/z 3195) showed the highest area under the receiver operating characteristic curve (AUROC = 0.799) for the diagnosis of pancreatic cancer. The ratio of pairs of glycans on the same path of the biosynthesis pathway (m/z 3195/1914) was found to be significantly higher in pancreatic cancer than in HLT (median = 1.11 and 0.41, respectively; p < 0.0001, AUROC = 0.831). For this pair ratio, the hazard ratio for survival (2.60, 95 % CI = 1.44-4.79) was higher than that of any single glycan and 1-year survival of patients with a high and low ratio was 36.9 and 69.2 %, respectively, (p = 0.001). CONCLUSIONS: Comprehensive glycome analysis can be used to know the presence of pancreatic cancer, distant metastasis, and patient prognosis, simultaneously.

    DOI: 10.1007/s00535-012-0732-7

    PubMed

    researchmap

  • Prognotic impact of serum follistatin in patients with hepatocellular carcinoma. 国際誌

    Takeshi Tomoda, Kazuhiro Nouso, Koji Miyahara, Sayo Kobayashi, Hideaki Kinugasa, Junki Toyosawa, Hiroaki Hagihara, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Fusao Ikeda, Yasuhiro Miyake, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

    Journal of gastroenterology and hepatology   28 ( 8 )   1391 - 6   2013年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed. METHODS: Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients. RESULTS: Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661 pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (P = 0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio = 2.41, 95% confidence interval = 1.16-5.00, P = 0.02). CONCLUSIONS: Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.

    DOI: 10.1111/jgh.12167

    PubMed

    researchmap

  • The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.

    Yasuto Takeuchi, Fusao Ikeda, Yuki Moritou, Hiroaki Hagihara, Tetsuya Yasunaka, Kenji Kuwaki, Yasuhiro Miyake, Hideki Ohnishi, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Yoshiaki Iwasaki, Kazuhiro Nouso, Kazuhide Yamamoto

    Journal of gastroenterology   48 ( 3 )   405 - 12   2013年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The single nucleotide polymorphism (SNP) rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat accumulation and disease progression in patients with non-alcoholic fatty liver disease and alcoholic liver disease (ALD). This study was conducted to determine whether PNPLA3 rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in patients with various liver diseases. METHODS: We enrolled 638 consecutive Japanese patients newly diagnosed with HCC between 2001 and 2010: 72 patients with hepatitis B virus (HBV), 462 with hepatitis C virus (HCV), and 104 with non-B non-C (NBNC). RESULTS: NBNC patients exhibited large tumors of advanced TNM stages at HCC diagnosis, and had significantly poorer prognosis than HBV or HCV patients (P < 0.001 and <0.001, respectively; log-rank test). The G/G genotype of PNPLA3 rs738409 SNP had significantly higher distribution in NBNC patients (P < 0.001) and was significantly associated with higher body mass index (BMI) and an increased aspartate aminotransferase to platelet ratio index. No significant differences were observed in survival with differences in PNPLA3 SNP genotypes among the patients, although ALD patients with the G/G genotype of PNPLA3 SNP and low BMI had significantly poorer survival than those with high BMI (P = 0.028). CONCLUSIONS: The G/G genotype of PNPLA3 rs738409 SNP was more frequently distributed, and associated with BMI and fibrosis among NBNC-HCC patients but not among HBV or HCV patients. These genotypes might affect HCC prognosis in ALD patients, but not in HBV, HCV, or NAFLD patients.

    DOI: 10.1007/s00535-012-0647-3

    PubMed

    researchmap

  • The diagnosis of hypovascular hepatic lesions showing hypo-intensity in the hepatobiliary phase of Gd-EOB- DTPA-enhanced MR imaging in high-risk patients for hepatocellular carcinoma.

    Shinichiro Nakamura, Kazuhiro Nouso, Yoshiyuki Kobayashi, Hidenori Shiraha, Hideki Ohnishi, Junichi Toshimori, Kenji Kuwaki, Hiroaki Hagihara, Hiroki Takayama, Kazuhide Yamamoto

    Acta medica Okayama   67 ( 4 )   239 - 44   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aim of this study was to evaluate the histologic diagnosis of hypovascular hepatic lesions showing hypointensity on hepatobiliary phase images of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI (EOB-MRI). In 38 patients with hepatocellular carcinoma (HCC) after curative treatments and 18 patients with liver cirrhosis, 105 hypovascular nodules that were hypointense at the hepatobiliary phase of EOB-MRI were biopsied and the clinical usefulness of these EOB-MRI findings for the diagnosis of HCC was examined. Of the 105 nodules (median diameter = 12mm), 78 (74.3%), 11 (10.5%), and 16 (15.2%) were diagnosed as HCC, dysplastic, and non-neoplastic, respectively. The positive predictive value (PPV) of hypointensity at the hepatobiliary phase of EOB-MRI for the diagnosis of HCC increased to 77-90% when combined with the following factors: washout appearance on the delayed phase of triple-phase CT, hyperintensity in diffusion-weighted image of MRI, or the appearance of a hypoechoic part in ultrasonography. PPV increased to 100% when all 3 factors were positive. A relatively large proportion of hypovascular lesions that showed hypo-intensity in the hepatobiliary phase were confirmed to be HCC, and the accuracy of HCC increased when combined with other imaging findings.

    PubMed

    researchmap

  • Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. 国際誌

    Shigetomi Tanaka, Hidenori Shiraha, Yutaka Nakanishi, Shin-Ichi Nishina, Minoru Matsubara, Shigeru Horiguchi, Nobuyuki Takaoka, Masaya Iwamuro, Junro Kataoka, Kenji Kuwaki, Hiroaki Hagihara, Junichi Toshimori, Hideki Ohnishi, Akinobu Takaki, Shinichiro Nakamura, Kazuhiro Nouso, Takahito Yagi, Kazuhide Yamamoto

    International journal of cancer   131 ( 11 )   2537 - 46   2012年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Loss or decreased expression of runt-related transcription factor 3 (RUNX3), a tumor suppressor gene involved in gastric and other cancers, has been frequently observed in hepatocellular carcinoma (HCC). The objective of this study was to identify the regulatory mechanism of the epithelial-mesenchymal transition (EMT) by RUNX3 in HCC. Human HCC cell lines, Hep3B, Huh7, HLF and SK-Hep1, were divided into low- and high-EMT lines, based on their expression of TWIST1 and SNAI2, and were used in this in vitro study. Ectopic RUNX3 expression had an anti-EMT effect in low-EMT HCC cell lines characterized by increased E-cadherin expression and decreased N-cadherin and vimentin expression. RUNX3 expression has previously been reported to reduce jagged-1 (JAG1) expression; therefore, JAG1 ligand peptide was used to reinduce EMT in RUNX3-expressing low-EMT HCC cells. Immunohistochemical analyses were performed for RUNX3, E-cadherin, N-cadherin and TWIST1 in 33 human HCC tissues, also divided into low- and high-EMT HCC, based on TWIST1 expression. E-cadherin expression was correlated positively and N-cadherin expression was correlated negatively with RUNX3 expression in low-EMT HCC tissues. Correlations between EMT markers and RUNX3 mRNA expression were analyzed using Oncomine datasets. Similarly, mRNA expression of E-cadherin was also significantly correlated with that of RUNX3 in low-EMT HCC, while mRNA expression of JAG1 was negatively correlated with that of RUNX3. These results suggest a novel mechanism by which loss or decreased expression of RUNX3 induces EMT via induction of JAG1 expression in low-EMT HCC.

    DOI: 10.1002/ijc.27575

    PubMed

    researchmap

  • Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma. 国際誌

    Sayo Kobayashi, Kazuhiro Nouso, Hideaki Kinugasa, Yasuto Takeuchi, Takeshi Tomoda, Koji Miyahara, Hiroaki Hagihara, Kenji Kuwaki, Hideki Onishi, Shinichiro Nakamura, Fusao Ikeda, Yasuhiro Miyake, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   42 ( 12 )   1187 - 95   2012年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM:   Hepatocellular carcinoma (HCC) is a common clinical problem all over the world. Fucosylated hemopexin (Fuc-Hpx) is a newly reported glycoprotein for the diagnosis of HCC, however, its clinical implications are unclear. The aim of this study was to elucidate the clinical utility of Fuc-Hpx in Japanese patients with HCC. METHODS:   The sera from 331 HCC patients, 45 with liver cirrhosis (LC), 85 with chronic hepatitis (CH) and 22 healthy people were examined for the expression of Fuc-Hpx; the level was compared with clinical parameters as well as hemopexin (Hpx) expression. The expressions of Fuc-Hpx in 12 HCC tissues and corresponding adjacent non-cancerous liver tissues were also examined. RESULTS:   No correlation was observed between Hpx and Fuc-Hpx level. The median Fuc-Hpx levels in healthy people and CH, LC and HCC patients were 3.8, 3.7, 6.1 and 7.6 AU/mL, respectively (CH vs LC, P = 0.002; CH vs HCC, P < 0.001; LC vs HCC, P = 0.02). Multivariate analysis revealed that low albumin, low prothrombin time and the presence of HCC were significantly correlated with high Fuc-Hpx (P = 0.013, =0.001 and <0.001, respectively). Among the HCC patients, albumin was correlated with high Fuc-Hpx; however, none of the tumor factors, such as tumor size, tumor number and tumor stage, was correlated with Fuc-Hpx level. The expression of Fuc-Hpx in cancer tissue was not different from that in non-cancerous tissue. CONCLUSION:   Fuc-Hpx is a valuable biomarker for HCC but it might be a marker for hypercarcinogenic liver rather than a marker for tumor-bearing liver.

    DOI: 10.1111/j.1872-034X.2012.01044.x

    PubMed

    researchmap

  • Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. 国際誌

    Hirokazu Miyatake, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shin-Ichiro Nakamura, Hideki Ohnishi, Kenji Kuwaki, Junichi Toshimori, Hiroaki Hagihara, Kazuhiro Nouso, Kazuhide Yamamoto

    Digestive diseases and sciences   57 ( 4 )   1092 - 101   2012年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in HCV-related HCC patients. METHODS: Three hundred ninety-five patients who underwent curative treatment for HCV-related HCC were enrolled. Of these, 124 had received IFN treatment before the development of HCC (17 achieved sustained virological response [SVR group] and 107 did not [non-SVR group]), whereas 271 patients had never received IFN treatment (IFN-untreated group). The first and second recurrence and survival rates in these patient groups were statistically analyzed. RESULTS: The first HCC recurrence rate was similar among patient groups. In contrast, the second HCC recurrence rate was significantly lower in the SVR group than in the non-SVR group (p = 0.003) and the IFN-untreated group (p = 0.006). In multivariate analysis, platelet count (p = 0.033) and number of tumors (p = 0.001) were associated with the first HCC recurrence, while SVR (p = 0.002) was the only factor associated with the second HCC recurrence. The survival rate was higher in the SVR group than in non-SVR and IFN-untreated groups, and SVR to previous IFN treatment was an independent factor associated with better survival (p < 0.001). CONCLUSIONS: SVR to previous IFN treatment before the development of HCV-related HCC was associated with lower risk of the second recurrence of HCC and better survival.

    DOI: 10.1007/s10620-011-1934-1

    PubMed

    researchmap

  • Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.

    Hideaki Kinugasa, Kazuhiro Nouso, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Onishi, Shin-ichiro Nakamura, Hidenori Shiraha, Kenji Kuwaki, Hiroaki Hagihara, Fusao Ikeda, Yasuhiro Miyake, Akinobu Takaki, Kazuhide Yamamoto

    Journal of gastroenterology   47 ( 4 )   421 - 6   2012年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Radiofrequency ablation (RFA) is a standard therapy for the treatment of hepatocellular carcinoma (HCC) with 3 or fewer tumors of up to 3 cm (early-stage HCC); when RFA is unsuccessful or unfeasible, transcatheter arterial chemoembolization (TACE) has often been performed. However, little information about the outcome of TACE for early-stage HCC has been reported and it is hard to decide whether to perform additional treatment following TACE in these difficult conditions. The aim of this study was to determine the risk factors for local or intrahepatic distant recurrence after TACE in early-stage HCC. METHODS: Among 1,560 newly diagnosed HCC patients who were admitted to Okayama University Hospital, 43 patients with early-stage HCC who received only TACE in at least one nodule were enrolled in this study. We analyzed the risk factors for local and distant recurrence by the Cox proportional hazard model. RESULTS: The local recurrence rates and intrahepatic distant recurrence rates at 3 months, 6 months, and 1 year were 18.6, 33.4, and 61.8%, and 2.8, 2.8, and 34.3%, [corrected] respectively.Among 12 parameters examined as possible risk factors for recurrence, heterogeneous Lipiodol uptake (risk ratio 3.38; 95% confidence interval 1.14-10.60) and high serum des-gamma-carboxy prothrombin (DCP) (2.58; 1.03-7.14) were significantly correlated with local recurrence, and the presence of multiple tumors (10.64; 1.76-93.75) was significantly correlated with intrahepatic distant recurrence. CONCLUSIONS: Heterogeneous Lipiodol uptake, high serum DCP, and multiple tumors are risk factors for recurrence in patients with early-stage HCC who have undergone palliative TACE.

    DOI: 10.1007/s00535-011-0492-9

    PubMed

    researchmap

  • Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. 国際誌

    Takeshi Tomoda, Kazuhiro Nouso, Akiko Sakai, Mamoru Ouchida, Sayo Kobayashi, Koji Miyahara, Hideki Onishi, Shinichiro Nakamura, Kazuhide Yamamoto, Kenji Shimizu

    Journal of gastroenterology and hepatology   27 ( 4 )   797 - 804   2012年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Chronic hepatitis C virus (HCV) infection is a well known risk factor for hepatocellular carcinoma (HCC). The aim of this study is to elucidate the genetic risk of development and recurrence of HCC in patients with HCV. METHODS: A total of 468 patients with HCV, including 265 with HCC were enrolled. We genotyped 88 single nucleotide polymorphisms (SNPs) in 81 genes expected to influence hepatocarcinogenesis using the iPLEX assay. Risk of HCC was clarified by stratifying patients into risk groups based on the multiplied odds ratio (MOR) for SNPs associated with HCC, and the cumulative effects on the development and recurrence of HCC were analyzed. RESULTS: Six SNPs associated with risk of HCC were identified (OR range: 0.29-1.76). These included novel SNPs for hepatocarcinogenesis with HCV CCND2 rs1049606, RAD23B rs1805329, CEP164 rs573455, and GRP78rs430397 in addition to the known SNPs MDM2 rs2279744 and ALDH2 rs671. MOR analysis revealed that the highest risk group exerted about a 19-fold higher relative OR compared with the lowest risk group (P = 1.08 × 10(-5)). Predicted 10-year HCC risk ranged from 1.7% to 96% depending on the risk group and the extent of fibrosis. Recurrence-free survival of radiofrequency ablation-treated HCC in the high risk group (n = 53) was lower than that of low risk group (n = 58, P = 0.038). CONCLUSION: Single nucleotide polymorphisms of CCND2, RAD23B, GRP78, CEP164, MDM2, and ALDH2 genes were significantly associated with development and recurrence of HCC in Japanese patients with HCV.

    DOI: 10.1111/j.1440-1746.2011.06948.x

    PubMed

    researchmap

  • Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. 国際誌

    Koji Miyahara, Kazuhiro Nouso, Takeshi Tomoda, Sayo Kobayashi, Hiroaki Hagihara, Kenji Kuwaki, Junichi Toshimori, Hideki Onishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

    Journal of gastroenterology and hepatology   26 ( 11 )   1604 - 11   2011年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Sorafenib, the first agent demonstrated to have efficacy to improve the survival of patients with advanced hepatocellular carcinoma (HCC), is an active multikinase inhibitor affecting angiogenesis and tumor proliferation. We analyzed cytokines related to angiogenesis or cell proliferation, and tried to determine their utility as biomarkers of sorafenib treatment effect for HCC. METHODS: Nine serum cytokines (angiopoietin-2 [Ang-2], follistatin, granulocyte colony-stimulating factor [G-CSF], hepatocyte growth factor [HGF], interleukin-8 [IL-8], leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor) were measured in 30 HCC patients treated with sorafenib, and the effects of treatment were compared using modified Response Evaluation Criteria in Solid Tumors. RESULTS: All but IL-8 were significantly higher at baseline in patients with progressive disease. Progression-free survival was significantly shorter in patients with high levels of Ang-2, G-CSF, HGF, and leptin, and the hazard ratios were 2.51, 6.89, 2.55, and 4.14, respectively. As the number of cytokines at a high level increased, the treatment response deteriorated. Disease progression was seen in three of 12 (25.0%) patients with zero to two high biomarkers, two of six (33.3%) patients with 3-5 high biomarkers, and 10 of 12 (83.3%) patients with six to eight high biomarkers (P=0.008). The prognosis of all patients with eight high biomarkers was progressive disease. CONCLUSION: High levels of serum cytokines at baseline were correlated with poor effects of sorafenib treatment in patients with HCC.

    DOI: 10.1111/j.1440-1746.2011.06887.x

    PubMed

    researchmap

  • Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. 国際誌

    Kazuhiro Nouso, Yoshiyuki Kobayashi, Shinichiro Nakamura, Sayo Kobayashi, Hiroki Takayama, Junichi Toshimori, Kenji Kuwaki, Hiroaki Hagihara, Hideki Onishi, Yasuhiro Miyake, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Yoshiaki Iwasaki, Haruhiko Kobashi, Kazuhide Yamamoto

    Journal of gastroenterology and hepatology   26 ( 7 )   1195 - 200   2011年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Fucosylated alpha-fetoprotein (AFP-L3) is known to be a marker of poor prognosis in patients with hepatocellular carcinoma (HCC). However, it has been difficult to measure AFP-L3 under low AFP (≤ 20 ng/mL). The aim of this study was to elucidate the role of AFP-L3 in HCC patients with low AFP conditions. METHODS: One hundred and ninety six consecutive newly developed HCC patients with low AFP (≤ 20 ng/mL) were examined for serum AFP-L3 expression by a newly-developed micro-total analysis system that could stably measure AFP-L3 in low AFP circumstances, and its clinical importance was analyzed. RESULTS: Positivity of AFP-L3 in HCC patients was 13.3% at a cut-off level of 10%. Five-year survivals of HCC patients with AFP-L3 (< 10%) and AFP-L3 (≥ 10%) were 69.4% and 41.1%, respectively (P = 0.001). Among 18 clinical parameters, low alanine aminotransferase, large tumor size, presence of portal vein tumor thrombus, high AFP and high des-gamma carboxy prothrombin were observed in the high AFP-L3 (≥ 10%) group. Multivariate analysis revealed that high aspartate aminotransferase (AST) (risk ratio [RR]= 3.24, 95% confidence interval [CI] = 1.27-8.26), the presence of ascites (RR = 3.44, 95% CI = 1.22-9.34), multiple tumor number (RR= 3.06, 95% CI = 1.33-7.17), and high AFP-L3 (RR = 8.36, 95% CI= 2.79-25.5) were risk factors for survival. High AFP-L3 was also a risk factor for survival in HCC patients who received radiofrequency ablation (P = 0.048). CONCLUSIONS: AFP-L3 is a strong prognostic factor for survival even in HCC patients with low AFP (≤ 20 ng/mL).

    DOI: 10.1111/j.1440-1746.2011.06720.x

    PubMed

    researchmap

  • Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.

    Hiroaki Hagihara, Kazuhiro Nouso, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Kenji Kuwaki, Junichi Toshimori, Hirokazu Miyatake, Hideki Ohnishi, Hidenori Shiraha, Kazuhide Yamamoto

    International journal of clinical oncology   16 ( 3 )   210 - 20   2011年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. METHODS: Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. RESULTS: The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91%) was significantly higher than that in the non-IFN group (56%; P < 0.01). The rate of the second recurrence but not that of the first recurrence of HCC in the sustained virological responder (SVR) group was lower than that in the non-IFN group (P = 0.03). Improvement of survival by PEG-IFN and low rate of second recurrence in the SVR group were also observed in PS matched analysis. Multivariate analysis revealed that PEG-IFN therapy and high serum albumin were good prognostic factors for survival. Although low serum albumin and large and multiple tumors were risk factors for the first recurrence, non-SVR and low serum albumin were risk factors for the second recurrence. CONCLUSION: PEG-IFN-therapy after curative treatment of HCC improved the rate of survival, and SVR was found to be closely correlated with the prevention of recurrence.

    DOI: 10.1007/s10147-010-0150-x

    PubMed

    researchmap

  • Hepatocellular carcinoma occurring in hepatobiliary fibropolycystic disease. 国際誌

    Hideaki Kinugasa, Kazuhiro Nouso, Yoshiyuki Kobayashi, Tetuya Yasunaka, Hideki Onishi, Shin-Ichiro Nakamura, Hidenori Shiraha, Hiroki Takayama, Junichi Toshimori, Kenji Kuwaki, Hiroaki Hagihara, Yasuhiro Miyake, Fusao Ikeda, Akinobu Takaki, Haruhiko Kobashi, Kazuhide Yamamoto

    Hepatology research : the official journal of the Japan Society of Hepatology   41 ( 3 )   277 - 81   2011年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Congenital hepatic fibrosis (CHF) and bile duct hamartomas (von Meyenburg complexes) are hepatobiliary fibropolycystic diseases. There have been several reports of liver neoplasias arising in hepatobiliary fibropolycystic diseases. However, most of them were cholangiocarcinomas and cases involving hepatocellular carcinoma (HCC) are rare. A 51-year-old woman was found to have multiple hepatic tumors by ultrasonography and enhanced computed tomography (CT) during a regular work-up for the recurrence of lung cancer and thyroid cancer, which had been surgically removed 4 and 3 years ago, respectively. Nodules were observed at S3, S5, and S6 (2 cm in diameter). All of the nodules were hyperattenuated at the early arterial phase, and the main tumor at S5 showed hypoattenuation at the delayed phase on dynamic CT and magnetic resonance imaging (MRI). HCC was suspected from these findings. She also suffered from multiple small cystic lesions in the liver. The surgically removed liver showed HCC arising in CHF, which is a rare histological finding.

    DOI: 10.1111/j.1872-034X.2010.00761.x

    PubMed

    researchmap

  • Prognostic model for hepatocellular carcinoma with time-dependent factors.

    Kenji Kuwaki, Kazuhiro Nouso, Yoshiyuki Kobayashi, Shinichiro Nakamura, Yoichi M Ito, Shouta Iwadou, Hiroaki Hagihara, Tetsuya Yasunaka, Junichi Toshimori, Hirokazu Miyatake, Kenji Miyoshi, Hideki Onishi, Yasuhiro Miyake, Bon Shoji, Akinobu Takaki, Hidenori Shiraha, Yoshiaki Iwasaki, Haruhiko Kobashi, Kazuhide Yamamoto

    Acta medica Okayama   65 ( 1 )   11 - 9   2011年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The purpose of this study was to build a prognostic model of hepatocellular carcinoma (HCC) using time-dependent covariates to re-evaluate the prognosis at any stage of the disease. The subjects were consecutive HCC patients who were treated at our institute between 1995 and 2007. We constructed time-fixed and time-dependent prognostic models with a training group (n=336) and compared the prognostic abilities between conventional Cancer of the Liver Italian Program (CLIP) scores, Japan Integrated Staging (JIS) scores, an Okuda classification, and our prognostic models in the testing group (n=227) with the c-index. The time-dependent prognostic model consisted of main tumor size, tumor number, portal vein invasion, distant metastasis, alpha-fetoprotein, des-gamma-carboxy prothrombin (DCP), bilirubin, and albumin and the weighted scores were set for each factor depending on the hazard ratio for the prognosis. The prognostic index was determined by summing the scores. The c-index values for the CLIP scores, JIS scores, Okuda classification, and our time-dependent model were 0.741, 0.727, 0.609, and 0.870, respectively. These results indicate that our time-dependent model can estimate the prognosis of HCC more precisely than traditional time-fixed models and can be used to re-predict the prognosis of HCC.

    PubMed

    researchmap

  • Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. 国際誌

    Yutaka Nakanishi, Hidenori Shiraha, Shin-ichi Nishina, Shigetomi Tanaka, Minoru Matsubara, Shigeru Horiguchi, Masaya Iwamuro, Nobuyuki Takaoka, Masayuki Uemura, Kenji Kuwaki, Hiroaki Hagihara, Junichi Toshimori, Hideki Ohnishi, Akinobu Takaki, Shinichiro Nakamura, Yoshiyuki Kobayashi, Kazuhiro Nouso, Takahito Yagi, Kazuhide Yamamoto

    BMC cancer   11   3 - 3   2011年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Runt-related transcription factor 3 (RUNX3) is known as a tumor suppressor gene for gastric cancer and other cancers, this gene may be involved in the development of hepatocellular carcinoma (HCC). METHODS: RUNX3 expression was analyzed by immunoblot and immunohistochemistry in HCC cells and tissues, respectively. Hep3B cells, lacking endogenous RUNX3, were introduced with RUNX3 constructs. Cell proliferation was measured using the MTT assay and apoptosis was evaluated using DAPI staining. Apoptosis signaling was assessed by immunoblot analysis. RESULTS: RUNX3 protein expression was frequently inactivated in the HCC cell lines (91%) and tissues (90%). RUNX3 expression inhibited 90±8% of cell growth at 72 h in serum starved Hep3B cells. Forty-eight hour serum starvation-induced apoptosis and the percentage of apoptotic cells reached 31±4% and 4±1% in RUNX3-expressing Hep3B and control cells, respectively. Apoptotic activity was increased by Bim expression and caspase-3 and caspase-9 activation. CONCLUSION: RUNX3 expression enhanced serum starvation-induced apoptosis in HCC cell lines. RUNX3 is deleted or weakly expressed in HCC, which leads to tumorigenesis by escaping apoptosis.

    DOI: 10.1186/1471-2407-11-3

    PubMed

    researchmap

  • Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. 国際誌

    Shouta Iwadou, Kazuhiro Nouso, Kenji Kuwaki, Yoshiyuki Kobayashi, Shinichiro Nakamura, Hironori Tanaka, Kenji Miyoshi, Hideki Ohnishi, Yasuhiro Miyake, Hidenori Shiraha, Yoshiaki Iwasaki, Yasushi Shiratori, Kazuhide Yamamoto

    Liver international : official journal of the International Association for the Study of the Liver   30 ( 7 )   1027 - 32   2010年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: There are many reports dealing with the risk factors for hepatocellular carcinoma (HCC) recurrence. However, in most of these reported studies, factors were analysed only at the initial treatment stage, and the predisposing factors for the recurrence during follow-up have not been well studied. The aim of this study is to evaluate the predisposing factors after treatments. METHODS: Two hundred and seventy-one consecutive HCC patients curatively treated between January 1994 and March 2004 were followed up and analysed. The recurrence rate was estimated by the Kaplan- Meier method and the predisposing factors were evaluated by time-fixed Cox regression analysis and by time-dependent covariate analysis using multiple parameters. RESULTS: The mean follow-up period was 4.86 years and recurrence was observed in 169 patients (62.4%). The recurrence rates were 27.9, 65.1 and 84.3% at 1, 3 and 5 years respectively. Among the variables determined before treatment, predisposing factors for recurrence were low serum albumin [< or =3.5 g/dl, hazard ratio (HR)=1.47, 95% confidence interval (CI)=1.07-2.01] and multiple tumour number (HR=2.04, 95% CI=1.46-2.84) by time-fixed multivariate analysis. In the time-dependent analysis, six variables with 12 013 plots were examined. The multivariate analysis revealed that high des- gamma-carboxy prothrombin (DCP > or =40 mAU/ml, HR=2.33, 95% CI=1.61-3.39), high alpha-fetoprotein (AFP > or =100 ng/ml, HR=2.01, 95% CI=1.3-3.35) and high alanine aminotransferase (ALT > or = 40 IU/L, HR= 1.52, 95% CI=1.1-2.1) were significant predisposing factors for recurrence. CONCLUSION: Predisposing factors for the recurrence of HCC after treatment are different from those before treatments and special cautions are required when AFP, DCP or ALT is high during follow-up.

    DOI: 10.1111/j.1478-3231.2010.02252.x

    PubMed

    researchmap

  • Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma. 国際誌

    Hideki Ohnishi, Kohsaku Sakaguchi, Kazuhiro Nouso, Yoshiyuki Kobayashi, Shinichiro Nakamura, Hironori Tanaka, Yasuhiro Miyake, Bon Shoji, Shouta Iwadou, Yasushi Shiratori

    Hepatology international   4 ( 3 )   562 - 8   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Hepatic lesions identified by computed tomography (CT) during arterial portography (CTAP) or CT hepatic arteriography (CTHA) in hepatocellular carcinoma (HCC) patients are sometimes too small to be diagnosed as HCC. We undertook this cohort study to assess whether these small lesions are actually HCC, and to clarify the effectiveness of these imaging examinations in a clinical setting. METHODS: We assessed the characteristics of 74 tiny lesions detected by CTAP and/or CTHA, but not by CT in 67 patients. RESULTS: Seven out of 10 nodules were histologically confirmed as HCC and 18 out of 64 lesions increased in size and showed typical findings of HCC during the follow-up period. Multivariate analysis revealed that the size of the main tumor (>30 mm in diameter) was associated with the presence of tiny additional HCC lesions (P = 0.002). CONCLUSIONS: These findings indicate that CTAP and CTHA are recommended for determining the stage of HCC, especially when the HCC nodule is larger than 30 mm in diameter.

    DOI: 10.1007/s12072-010-9190-6

    PubMed

    researchmap

  • Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. 国際誌

    Kazuhiro Nouso, Hironori Tanaka, Shuji Uematsu, Kunihiro Shiraga, Ryoichi Okamoto, Hideki Onishi, Shin-Ichiro Nakamura, Yoshiyuki Kobayashi, Yasuyuki Araki, Noriaki Aoki, Yasushi Shiratori

    Journal of gastroenterology and hepatology   23 ( 3 )   437 - 44   2008年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: The clinical features of hepatocellular carcinoma (HCC) and the medical environment are diverse in different geographic areas. The aim of this study is to evaluate the cost-effectiveness of the surveillance of HCC in different medical circumstances. METHODS: The Markov model focused on variables that differ from country to country and may change in the future, especially in regards to the proportion of small HCC detected incidentally. The target population was 45-year-old patients with Child-Pugh class A cirrhosis, and the intervention was surveillance with ultrasonography every 6 months. RESULTS: The additional cost of the surveillance was $US15 100, the gain in quality-adjusted life years (QALYs) was 0.50 years, and the incremental cost-effectiveness ratio (ICER) was $US29 900/QALY in a base-case analysis (annual incidence of HCC = 4%). If 40% of small HCC were detected incidentally without surveillance, the gain in QALY decreased to 0.15 and the ICER increased to $US47 900/QALY. The increase in the annual incidence of HCC to 8% resulted in the increase of QALYs to 0.81, and the decrease of the ICER to $US25 400/QALY. The adoption of liver transplantation increased the gain in QALYs and the ICER to 0.84 and $US59 900/QALY, respectively. CONCLUSIONS: The gain in QALYs and the ICER due to the surveillance of HCC varies between different patient subgroups and it critically depends on the rate of small HCC detected incidentally without surveillance, as well as the annual incidence of HCC and the adoption of liver transplantation.

    PubMed

    researchmap

  • Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. 国際誌

    Hironori Tanaka, Kazuhiro Nouso, Haruhiko Kobashi, Yoshiyuki Kobayashi, Shin-ichiro Nakamura, Yasuhiro Miyake, Hideki Ohnishi, Kenji Miyoshi, Shouta Iwado, Yoshiaki Iwasaki, Kohsaku Sakaguchi, Yasushi Shiratori

    Liver international : official journal of the International Association for the Study of the Liver   26 ( 5 )   543 - 51   2006年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The benefit of surveillance of hepatocellular carcinoma (HCC) for patients with hepatitis C virus (HCV) infection, in terms of long-term survival, has not yet been established. METHODS: A total of 384 consecutive anti-HCV-positive HCC patients admitted to our hospital between January 1991 and October 2003 were enrolled. Patients were categorized into two groups, a surveillance group (182 patients) and a non-surveillance group (202 patients), according to tumor detection in a surveillance program based on periodical examination via ultrasound sonography and alpha fetoprotein determination at 6-month intervals, and their survival rates were compared. RESULTS: Although there were no significant differences in age and Child-Pugh classes between the two groups, the surveillance group exhibited a smaller tumor size (19 vs. 35 mm) and a higher incidence of single HCC (67% vs. 46%), compared with the non-surveillance group (each, P < 0.001). The cumulative survival rate in the surveillance group was higher than that in the non-surveillance group (5 years survival, 46% vs. 32%, P < 0.001). When the survival after correction of the lead-time bias in the surveillance group was analyzed according to the Child-Pugh classification, the surveillance program was found to have had a favorable outcome in Child-Pugh class A patients, but not in Child-Pugh class B/C patients. CONCLUSIONS: HCC surveillance for patients with HCV infection can lead to discovery of tumors at an early stage, especially in Child-Pugh class A, resulting in a favorable outcome.

    PubMed

    researchmap

▼全件表示

書籍等出版物

  • メディカテー血管内治療の薬ケアブックー

    ( 担当: 共著)

    メディカ出版  2019年9月 

     詳細を見る

    記述言語:日本語

    researchmap

  • 肝動注化学療法はどのような症例に適応があるか?

    大西秀樹,能祖一裕( 担当: 共著)

    メジカルビュー社  2015年3月 

     詳細を見る

    記述言語:日本語

    researchmap

  • 門脈腫瘍栓合併肝細胞癌への放射線療法の治療効果.(共著)

    大西秀樹, 能祖一裕, 小林功幸, 白羽英則, 中村進一郎, 三宅康広, 歳森淳一, 桑木健志, 萩原宏明, 山本和秀( 担当: 共著)

    2012年1月 

     詳細を見る

    記述言語:日本語

    researchmap

講演・口頭発表等

  • トルバプタンを導入した肝硬変患者における血管拡張抑制物質ADMA測定の意義

    竹内康人, 大山淳史, 足立卓哉, 和田 望, 大西秀樹, 白羽英則, 高木章乃夫, 岡田裕之

    第44回日本肝臓学会西部会  2021年12月9日 

     詳細を見る

    開催年月日: 2021年12月9日 - 2021年12月10日

    会議種別:口頭発表(一般)  

    researchmap

  • アテゾリズマブ・ベバシズマズの併用療法の実臨床での治療効果

    足立卓哉, 能祖一裕, 大山淳史, 和田 望, 竹内康人, 大西秀樹, 白羽英則, 高木章乃夫, 守屋昭男, 小橋春彦, 岩堂昭太, 岡田裕之

    第44回日本肝臓学会西部会  2021年12月9日 

     詳細を見る

    開催年月日: 2021年12月9日 - 2021年12月10日

    会議種別:口頭発表(一般)  

    researchmap

  • 肝臓内科医から見たFALD 招待

    大西秀樹

    第119回 日本循環器学会中国地方会  2021年11月27日 

     詳細を見る

    開催年月日: 2021年11月27日

    記述言語:日本語   会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

    researchmap

  • Fontan関連肝疾患を背景に肝細胞腺腫を発症した一例

    國富恵実, 大西秀樹, 大山淳史, 足立卓哉, 和田 望, 竹内康人, 白羽英則, 高木章乃夫, 岡田裕之

    第116回日本消化器病学会中国支部例会  2021年11月20日 

     詳細を見る

    開催年月日: 2021年11月20日 - 2021年11月21日

    会議種別:口頭発表(一般)  

    researchmap

  • アテゾリズマブとベバシズマブの併用療法における1st ライン使用と2ndライン以降の違いについて

    足立卓哉, 能祖一裕, 大山淳史, 和田 望, 竹内康人, 大西秀樹, 白羽英則, 高木章乃夫, 狩山和也, 岩堂昭太, 守屋昭男, 岡田裕之

    第25回日本肝臓学会大会  2021年11月4日 

     詳細を見る

    開催年月日: 2021年11月4日 - 2021年11月5日

    会議種別:ポスター発表  

    researchmap

  • トルバプタンによる腹水治療に伴う肝移植時状態の変化

    和田 望, 高木章乃夫, 大山淳史, 足立卓哉, 竹内康人, 大西秀樹, 白羽英則, 岡田裕之

    第25回日本肝臓学会大会  2021年11月4日 

     詳細を見る

    開催年月日: 2021年11月4日 - 2021年11月5日

    会議種別:ポスター発表  

    researchmap

  • Fontan術後に発生した肝細胞癌の2例

    森本光作, 大西秀樹, 高木章乃夫, 大山淳史, 足立卓哉, 和田 望, 竹内康人, 安中哲也, 白羽英則, 能祖一裕, 岡田裕之

    第57回日本肝癌研究会  2021年7月23日 

     詳細を見る

    開催年月日: 2021年7月22日 - 2021年7月23日

    会議種別:口頭発表(一般)  

    researchmap

  • アテゾリズマブとベバシズマズの併用療法とレンバチニブ治療の違い

    足立卓哉, 能祖一裕, 大山淳史, 和田 望, 竹内康人, 大西秀樹, 白羽英則, 高木章乃夫, 狩山和也, 岩堂昭太, 詫間義隆, 植松周二, 岡田裕之

    第57回日本肝癌研究会  2021年7月22日 

     詳細を見る

    開催年月日: 2021年7月22日 - 2021年7月23日

    会議種別:口頭発表(一般)  

    researchmap

  • 当院におけるSVR後発癌リスクの検討

    竹内康人, 大山淳史, 足立卓哉, 和田 望, 安中哲也, 大西秀樹, 白羽英則, 高木章乃夫, 能祖一裕, 岡田裕之

    第57回日本肝癌研究会  2021年7月22日 

     詳細を見る

    開催年月日: 2021年7月22日 - 2021年7月23日

    会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 肝癌に対する脳死肝移植適応基準の拡大による寄与

    高木章乃夫, 和田 望, 大山淳史, 足立卓哉, 大西秀樹, 白羽英則, 吉田龍一, 楳田祐三, 八木孝仁, 岡田裕之

    第57回日本肝癌研究会  2021年7月22日 

     詳細を見る

    開催年月日: 2021年7月22日 - 2021年7月23日

    会議種別:口頭発表(一般)  

    researchmap

  • 移行期医療におけるFontan関連肝疾患(FALD)診療の現状と問題

    大西秀樹, 高木章乃夫, 岡田裕之

    第57回 日本肝臓学会総会  2021年6月18日 

     詳細を見る

    開催年月日: 2021年6月17日 - 2021年6月18日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 肝癌に対するREIC/Dkk-3遺伝子治療開発

    白羽英則, 大山淳史, 岩室雅也, 小橋真由, 足立卓哉, 和田 望, 竹内康人, 安中哲也, 大西秀樹, 高木章乃夫, 岡田裕之

    第57回 日本肝臓学会総会  2021年6月17日 

     詳細を見る

    開催年月日: 2021年6月17日 - 2021年6月18日

    会議種別:口頭発表(一般)  

    researchmap

  • 高齢者においても有用な非侵襲的NAFLD線維化診断方法の探索

    森本光作, 竹内康人, 高木章乃夫, 大山淳史, 足立卓哉, 和田 望, 大西秀樹, 白羽英則, 岡田裕之

    第57回 日本肝臓学会総会  2021年6月17日 

     詳細を見る

    開催年月日: 2021年6月17日 - 2021年6月18日

    会議種別:口頭発表(一般)  

    researchmap

  • 好中球性白血病との鑑別が問題となったアルコール性肝炎増悪による急性肝不全症例

    稲生祥子, 安中哲也, 高木章乃夫, 大山淳史, 足立卓哉, 和田 望, 竹内康人, 大西秀樹, 白羽英則, 岡田裕之

    第115回日本消化器病学会中国支部例会  2021年6月12日 

     詳細を見る

    開催年月日: 2021年6月12日

    会議種別:口頭発表(一般)  

    researchmap

  • 肝臓内科医から見たFALD ~どう対処すれば良いのか~ 招待

    大西秀樹

    ACHD Night  2021年5月21日 

     詳細を見る

    開催年月日: 2021年5月21日

    記述言語:日本語   会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

    researchmap

  • 肝癌に対する脳死肝移植適応基準の拡大による実地診療への寄与

    和田望,高木章乃夫,大山淳史,足立卓哉,安中哲也,坂田雅浩,大西秀樹,白羽英則,吉田一博,高木弘誠,杭瀬崇,吉田龍一,楳田祐三,八木孝仁,岡田裕之

    第38回日本肝移植学会学術総会 

     詳細を見る

    開催年月日: 2020年12月25日 - 2020年12月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 進行肝細胞癌に対する 分子標的治療薬における 血管新生サイトカインの位置づけ

    足立卓哉,能祖一裕,大山淳史,和田望,竹内康人,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第56回日本肝癌研究会 

     詳細を見る

    開催年月日: 2020年12月22日 - 2020年12月23日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝細胞癌の集学的治療における体幹部定位放射線治療の役割

    大西秀樹,高木章乃夫,岡田裕之

    第56回日本肝癌研究会 

     詳細を見る

    開催年月日: 2020年12月22日 - 2020年12月23日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 偶発的に指摘された肝粘液嚢胞性腫瘍(MCN)の1例

    大山淳史,足立卓哉,和田望,竹内康人,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第114回日本消化器病学会中国支部例会 

     詳細を見る

    開催年月日: 2020年12月5日 - 2020年12月6日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 遠隔転移を有する進行肝細胞癌の分子標的治療薬治療とFollistainの関連性

    足立卓哉,能祖一裕,大山淳史,和田望,竹内康人,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第22回日本肝がん分子標的治療研究会 

     詳細を見る

    開催年月日: 2020年11月14日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 進行肝細胞癌に対する分子標的治療薬治療における血管新生サイトカインと既存腫瘍マーカーの位置づけ

    足立卓哉,能祖一裕,大山淳史,和田望,竹内康人,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    JDDW 2020 

     詳細を見る

    開催年月日: 2020年11月5日 - 2020年11月7日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝硬変合併肺病変の移植後経過より見た病態

    大山淳史,高木章乃夫,足立卓哉,和田望,竹内康人,安中哲也,大西秀樹,白羽英則,岡田裕之

    第27回日本門脈圧亢進症学会総会 

     詳細を見る

    開催年月日: 2020年9月10日 - 2020年9月11日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 移行期医療におけるFontan関連肝疾患(FALD)の現状と問題点

    大西秀樹,高木章乃夫,岡田裕之

    第56回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2020年8月28日 - 2020年8月29日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:大阪  

    researchmap

  • 糖尿病外来患者における慢性肝疾患スクリーニングマーカーの検討

    大山淳史,高木章乃夫,足立卓哉,和田望,竹内康人,安中哲也,大西秀樹,白羽英則,岡田裕之

    第56回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2020年8月28日 - 2020年8月29日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:大阪  

    researchmap

  • 血管新生サイトカインは進行肝細胞癌に対するレンバチニブ治療の予測因子になりうる

    足立卓哉,能祖一裕,大山淳史,和田望,坂田雅浩,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第56回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2020年8月28日 - 2020年8月29日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:大阪  

    researchmap

  • 肝性浮腫患者のトルバプタン効果と予後の予測

    足立卓哉,高木章乃夫,佐藤秀一,大山淳史,和田望,坂田雅浩,安中哲也,大西秀樹,白羽英則,岡田裕之

    第56回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2020年8月28日 - 2020年8月29日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:大阪  

    researchmap

  • 成人先天性心疾患におけるFontan関連肝疾患(FALD)の現状と問題点

    大西秀樹, 高木章乃夫, 和田 望, 大山淳史, 足立卓哉, 坂田雅浩, 安中哲也, 白羽英則, 能祖一裕, 岡田裕之

    第106回日本消化器病学会総会  日本消化器病学会

     詳細を見る

    開催年月日: 2020年8月11日 - 2020年8月13日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:広島  

    researchmap

  • 糖尿病外来患者における慢性肝疾患スクリーニングマーカーの検討

    大山淳史,高木章乃夫,足立卓哉,和田望,竹内 康人,安中哲也,大西秀樹,白羽英則,岡田裕之

    第106回日本消化器病学会総会 

     詳細を見る

    開催年月日: 2020年8月11日 - 2020年8月13日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 経皮肝腫瘍生検にて診断しえた末梢型T細胞リンパ腫の1例

    大山淳史,大西秀樹,足立卓哉,和田望,高原政宏,坂田雅浩,安中哲也,平岡佐規子,丹羽知子,戸田由香,岡田裕之

    第113回日本消化器病学会中国支部例会 

     詳細を見る

    開催年月日: 2020年6月13日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 進?肝細胞癌に対するレンバチニブ 治療と?管新?サイトカインの関連性

    足立卓哉,能祖一裕,大山淳史,和田望,坂田雅浩,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第21回日本肝がん分子標的治療研究会 

     詳細を見る

    開催年月日: 2020年1月11日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝動注化学療法で奏功が期待できる肝細胞癌の臨床的特徴

    大西秀樹, 高木章乃夫, 和田 望, 大山淳史, 足立卓哉, 坂田雅浩, 安中哲也, 白羽英則, 能祖一裕, 岡田裕之

    第43回日本肝臓学会西部会  日本肝臓学会

     詳細を見る

    開催年月日: 2019年12月12日 - 2019年12月13日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:下関  

    researchmap

  • 肝癌根治的ラジオ波後予後不良に関連する再発例での血清酸化ストレスマーカーの評価

    室 泰子,高木章乃夫,中村進一郎,大西秀樹,岡田裕之

    第112回日本消化器病学会中国支部例会 

     詳細を見る

    開催年月日: 2019年11月30日 - 2019年12月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝障害を呈した骨髄性プロトポルフィリン症の1 例

    岡寿紀,安中哲也,荒木俊江,高木章乃夫,大山淳史,足立卓哉,和田望,坂田雅浩,大西秀樹,白羽英則,岡田裕之

    第112回日本消化器病学会中国支部例会 

     詳細を見る

    開催年月日: 2019年11月30日 - 2019年12月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝生検標本フローサイトメトリーにより早期診断と治療を開始し得た悪性リンパ腫の一例

    河原聡一郎,坂田雅浩,大山淳史,足立卓哉,和田望,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第112回日本消化器病学会中国支部例会 

     詳細を見る

    開催年月日: 2019年11月30日 - 2019年12月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 高齢者におけるDAA治療の現状

    和田 望, 大山 淳史, 足立 卓哉, 坂田 雅浩, 安中 哲也, 大西 秀樹, 池田 房雄, 白羽 英則, 高木 章乃夫, 岡田 裕之

    JDDW 2019 

     詳細を見る

    開催年月日: 2019年11月21日 - 2019年11月24日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • レンバチニブで長期効果見込める肝細胞癌症例の特徴

    足立 卓哉, 能祖 一裕, 大山 淳史, 和田 望, 坂田 雅浩, 安中 哲也, 大西 秀樹, 白羽 英則, 高木 章乃夫, 狩山 和也, 岡田 裕之

    JDDW 2019 

     詳細を見る

    開催年月日: 2019年11月21日 - 2019年11月24日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 原発性硬化性胆管炎(PSC)予後予測因子の検討

    大山 淳史, 高木 章乃夫, 足立 卓哉, 和田 望, 坂田 雅浩, 安中 哲也, 大西 秀樹, 白羽 英則, 岡田 裕之

    JDDW 2019 

     詳細を見る

    開催年月日: 2019年11月21日 - 2019年11月24日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • Predictio n of the prognosis of advanced hepato cellular carcinoma patients by hTERT promoter mutation in circulating tumor DNA

    Hirai M, Kinugasa H, Nouso K, Terasawa H, Yamamoto S, Oyama A, Adachi T, Wada N, Sakata M, Yasunaka T, Onishi H, Shiraha H, Takaki A, Okada H

    27th United European Gastroenterology Week 

     詳細を見る

    開催年月日: 2019年10月19日 - 2019年10月23日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • The Prognosti c facto rs for primary sclerosing cholangitis including oxidative stress markers

    Oyama A, Takaki A, Adachi T, Wada N, Sakata M, Yasunaka T, Onishi H, Shiraha H, Okada H

    27th United European Gastroenterology Week 

     詳細を見る

    開催年月日: 2019年10月19日 - 2019年10月23日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • CKDを伴う移植後C型肝炎に対するインターフェロンフリーDirect acting antivirals(DAA)治療の経験

    井川翔子,安中哲也,大山淳史,足立卓哉,和田 望,坂田雅浩,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第121回日本内科学会中国地方会 

     詳細を見る

    開催年月日: 2019年10月5日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 急激な増大を来した尿細管肝転移の1例

    大山淳史, 大西秀樹, 中村知子, 白羽英則, 高木章乃夫, 岡田裕之

    日本超音波医学会第55回中国地方学術集会 

     詳細を見る

    開催年月日: 2019年9月7日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • Which is the first choice for the treatment of advanced HCC, lenvatinib or sorafenib?

    Takuya Adachi, Kazuhiro Nouso, Atsushi Oyama, Nozomu Wada, Masahiro Sakata, Tetsuya Yasunaka, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    The 10thAsia-Pacific Primary Liver Cancer Expert Meeting 

     詳細を見る

    開催年月日: 2019年8月29日 - 2019年8月31日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • 肝移植周術期C型肝硬変治療の経験

    井川翔子, 高木章乃夫, 安中哲也, 大山淳史, 足立卓哉, 和田望, 坂田雅浩, 大西秀樹, 白羽英則, 岡田裕之, 吉田一博, 杭瀬崇, 吉田龍一, 楳田祐三, 八木孝仁

    第37回日本肝移植学会 

     詳細を見る

    開催年月日: 2019年7月25日 - 2019年7月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • どのような症例にレンバチニブは使用するべきか

    足立卓哉,能祖一裕,狩山和也,大山淳史,和田望,坂田雅浩,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第55回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2019年7月4日 - 2019年7月5日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 肝細胞癌に対する定位放射線治療の有用性

    大西秀樹, 高木章乃夫, 能祖一裕, 大山淳史, 足立卓哉, 和田 望, 坂田雅浩, 安中哲也, 白羽英則, 勝井邦彰, 金澤 右, 岡田裕之

    第55回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2019年7月4日 - 2019年7月5日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 分子標的治療薬の投薬状況から考えるそれぞれの症例の特徴

    足立卓哉,能祖一裕,大山淳史,和田望,坂田雅浩,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第20回日本肝がん分子標的治療研究会  日本肝がん分子標的治療研究会

     詳細を見る

    開催年月日: 2019年6月29日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝細胞癌根治治療後の無再発に寄与する因子としての酸化ストレスの重要性

    室 泰子, 高木章乃夫, 大西秀樹, 大山淳史, 足立卓哉, 和田 望, 坂田雅浩, 安中哲也, 白羽英則, 岡田裕之

    第55回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2019年5月30日 - 2019年5月31日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:東京  

    researchmap

  • 肝細胞癌根治的治療後の無再発に寄与する因子としての酸化ストレスの重要性

    室泰子,高木章乃夫,中村進一郎,大山淳史,足立卓哉,和田望,安中哲也,安中幸,竹内康人,大西秀樹,池田房雄,白羽英則,岡田裕之

    第55回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2019年5月30日 - 2019年5月31日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 肝細胞癌に対する定位放射線治療の有用性

    大西秀樹, 高木章乃夫, 能祖一裕, 大山淳史, 足立卓哉, 和田 望, 坂田雅浩, 安中哲也, 白羽英則, 勝井邦彰, 金澤 右, 岡田裕之

    第55回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2019年5月30日 - 2019年5月31日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • THE PROGNOSTIC FACTORS FOR PRIMARY SCLEROSING CHOLANGITIS (PSC) INCLUDING OXIDATIVE STRESS MARKER

    A. Oyama, A. Takaki, T. Adachi, N. Wada, M. Sakata, T. Yasunaka , H. Onishi , F. Ikeda , H. Shiraha, H. Shiraha and H. Okada

    Asian Pacific Association for the Study of the Liver Single Topic Conference  APASL

     詳細を見る

    開催年月日: 2019年4月18日 - 2019年4月20日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • レンバチニブ初期投与経験から 学ぶ治療効果予測因子と 有害事象

    足立卓哉,能祖一裕,大山淳史,和田望,坂田雅浩,安中哲也,大西秀樹,白羽英則,高木章乃夫,岡田裕之

    第19回日本肝がん分子標的治療研究会  日本肝がん分子標的治療研究会

     詳細を見る

    開催年月日: 2019年1月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • FontanーAssociated Liver Disease 招待

    大西秀樹

    第21回 日本成人先天性心疾患学会総会・学術集会  日本成人先天性心疾患学会

     詳細を見る

    開催年月日: 2019年1月11日 - 2019年1月13日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    開催地:岡山  

    researchmap

  • DCV+ASV併用療法でSVR24を達成した5か月後に再燃を認めたC型慢性肝炎の一例

    和田 望, 池田房雄, 大山淳史, 足立卓哉, 坂田雅浩, 安中哲也, 大西秀樹, 白羽英則, 高木章乃夫, 岡田 裕之

    第110回日本消化器病学会中国支部例会  日本消化器病学会

     詳細を見る

    開催年月日: 2018年12月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:鳥取  

    researchmap

  • 肝細胞癌に対してシスプラチン肝動注療法後に大腸炎を発症した一例

    山本峻平, 大西秀樹, 大山淳史, 足立卓哉, 和田 望, 坂田雅浩, 安中哲也, 池田房雄, 白羽英則 , 能祖一裕, 高木章乃夫, 岡田裕之

    第110回日本消化器病学会中国支部例会  日本消化器病学会

     詳細を見る

    開催年月日: 2018年12月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:鳥取  

    researchmap

  • 肝細胞癌に合併した骨髄癌腫症の一例

    上田英次郎, 大西秀樹 , 大山淳史, 足立卓哉, 和田 望, 坂田雅浩, 安中哲也, 池田房雄, 白羽英則, 高木章乃夫, 能祖一裕, 岡田裕之

    第119回日本内科学会中国地方会  日本内科学会

     詳細を見る

    開催年月日: 2018年11月17日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島  

    researchmap

  • DAA治療後のSVR後発癌の特徴

    和田 望, 竹内康人, 池田房雄, 大山淳史, 足立卓哉, 安中 幸, 安中哲也, 大西秀樹, 白羽英則, 高木章乃夫, 岡田裕之

    JDDW2018 

     詳細を見る

    開催年月日: 2018年11月1日 - 2018年11月4日

    会議種別:ポスター発表  

    researchmap

  • 造影超音波検査を施行し得た肝硬化型血管腫の1例

    戸田由香, 大西秀樹, 能勢資子, 中村知子, 大山淳史, 白羽英則, 高木章乃夫, 大塚文男, 岡田裕之

    日本超音波医学会第54回中国地方学術集会  日本超音波医学会

     詳細を見る

    開催年月日: 2018年9月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島  

    researchmap

  • 肝硬変に伴う肺血流動態異常の病態分類

    高木章乃夫, 大山淳史, 中村一文, 八木孝仁, 皿谷洋祐, 足立卓哉, 和田 望, 大西秀樹, 伊藤 浩, 岡田裕之

    日本超音波医学会第54回中国地方学術集会  日本超音波医学会

     詳細を見る

    開催年月日: 2018年9月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島  

    researchmap

  • 経皮肝腫瘍生検にて診断しえた末梢型T細胞リンパ腫の1例

    大山淳史, 大西秀樹, 足立卓哉, 池田愛璃, 高原政宏, 平岡佐規子, 高木章乃夫, 中村知子, 戸田由香, 岡田裕之

    日本超音波医学会第54回中国地方学術集会  日本超音波医学会

     詳細を見る

    開催年月日: 2018年9月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:広島  

    researchmap

  • 知って役立つ稀な肝疾患の超音波像 招待

    大西秀樹

    日本超音波医学会第17回中国地方会講習会  日本超音波医学会

     詳細を見る

    開催年月日: 2018年9月1日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    開催地:広島  

    researchmap

  • 肝細胞癌根治治療後の同一区域内再発症例では酸化ストレスマーカーも抗酸化力マーカーも低下している

    室 泰子, 高木章乃夫, 中村進一郎, 大西秀樹, 大山淳史, 足立卓哉, 和田 望, 竹内康人, 白羽英則, 岡田裕之

    第54回日本肝癌研究会 

     詳細を見る

    開催年月日: 2018年6月28日 - 2018年6月29日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝細胞癌根治後にDAAを投与した症例の再発に寄与する因子:多施設共同研究

    中村進一郎, 能祖一裕, 岡田裕之, 大西秀樹, 白羽英則, 池田房雄, 竹内康人, 高木章乃夫, 藤岡真一, 荒木康之, 岩堂昭太, 熊田 卓, 豊田秀徳, 本村健太, 狩山和也, 小橋春彦, 金吉俊彦, 田中正俊

    第54回日本肝癌研究会 

     詳細を見る

    開催年月日: 2018年6月28日 - 2018年6月29日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • ソラフェニブ投与中にHBV再活性化を認めた3症例の検討

    和田 望, 大西秀樹, 大山淳史, 足立卓哉, 竹内康人, 安中 幸, 安中哲也, 池田房雄, 白羽英則, 高木章乃夫, 岡田裕之

    第54回日本肝癌研究会 

     詳細を見る

    開催年月日: 2018年6月28日 - 2018年6月29日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • 血液検査による非B非C肝癌のリスク集団の絞り込み

    能祖一裕, 古林佳恵, 狩山和也, 大西秀樹, 高木章乃夫, 岡田裕之

    第54回日本肝癌研究会 

     詳細を見る

    開催年月日: 2018年6月28日 - 2018年6月29日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 肝動注化学療法が有効な肝細胞癌の臨床的特徴

    大西秀樹, 能祖一裕, 岡田裕之

    第54回日本肝臓学会総会 

     詳細を見る

    開催年月日: 2018年6月14日 - 2018年6月15日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 先天性心疾患患者における肝合併症の現状

    大西秀樹, 竹内康人, 岡田裕之

    第54回日本肝臓学会総会 

     詳細を見る

    開催年月日: 2018年6月14日 - 2018年6月15日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 非アルコール性脂肪性肝疾患における酸化ストレス評価と発癌も見据えた最適な抗酸化療法の探索

    大西秀樹, 能祖一裕, 岡田裕之

    第54回日本肝臓学会総会 

     詳細を見る

    開催年月日: 2018年6月14日 - 2018年6月15日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 胆管内発育型肝細胞癌に対して肝動注化学療法と放射線療法が奏効した1例

    坂口智紘, 足立卓哉, 大山淳史, 和田望 ,安中 幸, 安中哲也, 大西秀樹, 池田房雄, 白羽英則, 高木章乃夫

    第109回日本消化器病学会中国支部例会 

     詳細を見る

    開催年月日: 2018年6月9日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • Camptodactyly-arthropathy-coxa vara-pericarditis syndrome に合併した肝細胞癌 の1例

    池田 愛璃,竹内 康人,和田 望,安中 幸,大西 秀樹,中村 進一郎,白羽 英則, 高木 章乃夫,能祖 一裕,岡田 裕之

    第108回日本消化器病学会中国支部例会/第119回日本消化器内視鏡学会中国支部例会 

     詳細を見る

    開催年月日: 2017年11月25日 - 2017年11月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • シスプラチンを用いた肝動注療法後に renal salt wasting syndrome を来した 1 例

    濱田 健太,竹内 康人,和田 望,安中 幸,大西 秀樹,中村 進一郎,白羽 英則, 高木 章乃夫,岡田 裕之,北川 正史,御舩 朋代,細谷 武史,能祖 一裕

    第108回日本消化器病学会中国支部例会/第119回日本消化器内視鏡学会中国支部例会 

     詳細を見る

    開催年月日: 2017年11月25日 - 2017年11月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝細胞癌治療経過中に発症した後天性第 5 因子インヒビターの 1 例

    岡 昌平,白羽 英則,大山 淳史,足立 卓哉,和田 望,安中 幸,竹内 康人,安中 哲也, 大西 秀樹,池田 房雄,中村 進一郎,高木 章乃夫,能祖 一裕,岡田 裕之

    第108回日本消化器病学会中国支部例会/第119回日本消化器内視鏡学会中国支部例会 

     詳細を見る

    開催年月日: 2017年11月25日 - 2017年11月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝硬変患者の体液貯留に対するトルバプタン効果予測因子としての酸化ストレスマーカーの有用性

    "足立卓哉、高木章乃夫、佐藤秀一、大山淳史、和田望、安中幸、竹内康人、安中哲也、大西秀樹、池田房雄、中村進一郎、白羽英則、岡田裕之

    第24回日本門脈圧亢進症学会 

     詳細を見る

    開催年月日: 2017年9月14日 - 2017年9月15日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 特徴的な膵臓の超音波所見を呈したShwachman-Diamond症候群の一例

    中村知子, 中村進一郎, 竹内麻梨, 戸田由香, 竹内康人, 桑木健志, 大西秀樹, 白羽英則, 能祖一裕

    日本超音波医学会第53回中国地方学術集会 

     詳細を見る

    開催年月日: 2017年9月2日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 単心室症患者に合併したParagangliomaの一例

    竹内麻梨, 中村進一郎, 中村知子, 戸田由香, 安中 幸, 竹内康人, 桑木健志, 大西秀樹, 白羽英則, 能祖一裕

    日本超音波医学会第53回中国地方学術集会 

     詳細を見る

    開催年月日: 2017年9月2日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 進行肝細胞癌(HCC)に対するソラフェニブ治療の予後予測因子としての血管新生サイトカインの有用性の検討

    足立卓哉、能祖一裕、宮原孝治、土肥千紘、和田望、竹内康人、桑木健志、大西秀樹、池田房雄、中村進一郎、白羽英則、高木章乃夫、高口浩一、植松周二、高畠弘行、岡田裕之

    第53回 日本肝癌研究会 

     詳細を見る

    開催年月日: 2017年7月6日 - 2017年7月8日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    researchmap

  • 肝細胞癌における肝動注化学療法の臨床的役割

    大西秀樹,能祖一裕,中村進一郎,三木理恵,足立卓哉,大山淳史,和田望,竹内康人,安中幸,安中哲也,池田房雄,白羽英則,高木章乃夫,岡田裕之

    第53回 日本肝癌研究会 

     詳細を見る

    開催年月日: 2017年7月6日 - 2017年7月8日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    researchmap

  • 肝硬変体液貯留に対するトルバプタンの効果予測因子としての酸化ストレスの重要性

    足立卓哉、高木章乃夫、佐藤秀一、大山淳史、和田望、安中幸、竹内康人、安中哲也、大西秀樹、池田房雄、中村進一郎、白羽英則、岡田裕之

    第53回肝臓学会総会 

     詳細を見る

    開催年月日: 2017年6月8日 - 2017年6月9日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • Prospective confirmation of the factors predicting the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib

    Adachi T,Noso K,Miyahara K,Oyama A,Wada N,Dohi C,Takeuchi Y,Yasunaka T,Onishi H,Ikeda F,Nakamura S,Shiraha H,Takaki A,Takabatake H,Fujioka S,Kobashi H,Takuma Y,Iwadou S,Uematsu S,Takaguchi K,Hagihara H,Okada H

    ASCO2017 

     詳細を見る

    開催年月日: 2017年6月2日 - 2017年6月6日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • 移植後C型肝炎に対するインターフェロンフリーDAA治療の高い効果

    大山 淳史、高木 章乃夫、安中 哲也、足立 卓哉、和田 望、竹内康人、池田 房雄、大西秀樹、中村進一郎、白羽英則、楳田 祐三、吉田 龍一、信岡 大輔、杭瀬 崇、高木 弘誠、八木孝仁、岡田 裕之

    第35回日本肝移植研究会 

     詳細を見る

    開催年月日: 2017年6月1日 - 2017年6月2日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 穿刺用マイクロコンベックスプローブに求められるもの

    中村進一郎,大西秀樹,桑木健志,竹内康人,白羽英則,和田 望,安中 幸,能祖一裕,高木章乃夫,岡田裕之

    第90回日本超音波医学会総会 

     詳細を見る

    開催年月日: 2017年5月26日 - 2017年5月28日

    会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 肝動注化学療法から分子標的薬への切り替えのタイミング:肝機能と早期治療効果判定の観点から

    大西秀樹,能祖一裕,岡田裕之

    JDDW 2016 

     詳細を見る

    開催年月日: 2016年11月3日 - 2016年11月6日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • Radiofrequency ablation for the treatment of Intermediate stage hepatocellular carcinoma.

    Kazuhiro Nouso, Kazuya Kariyama, Ayano Oonishi, Akiko Wakuta, Chihiro Dohi, Nozomu Wada, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    The 12th JSH Sungle Topic Conference 

     詳細を見る

    開催年月日: 2016年9月22日 - 2016年9月23日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • 肝表面に隆起した肝細胞癌に対するラジオ波焼灼療法〜穿刺手技の工夫

    中村進一郎,大西秀樹,能祖一裕,桑木健志,竹内康人,白羽英則,安中 幸,安中哲也,森元裕貴,和田 望,池田房雄,高木章乃夫,岡田裕之

    第52回 日本肝癌研究会 

     詳細を見る

    開催年月日: 2016年7月1日 - 2016年7月2日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • Budd-Chiari症候群に伴う門脈圧亢進症に対し、肝静脈拡張術が奏効した1例

    大山淳史,池田愛璃,砂田匠彦,安藤智子,榮 浩行,森元裕貴,安中哲也,大西秀樹,楳田祐三,高木章乃夫,岡田裕之,八木孝仁

    第5回中国門脈圧亢進症研究会 

     詳細を見る

    開催年月日: 2016年6月10日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • The specific pattern of recurrence associated with poor prognosis after radiofrequency ablation for hepatocellular carcinoma

    Nakamura Shinichiro, Nouso Kazuhiro, Onishi Hideki, Kuwaki Kenji,Takeuchi Yasuto, Wada Nozomu, Morimoto Yuuki, Yasunaka Tetsuya, Yasunaka Yuki, Ikeda Fusao,Shiraha Hidenori, Takaki Akinobu, Yamamoto Kazuhide, Okada Hiroyuki

    DDW 2016 

     詳細を見る

    開催年月日: 2016年5月21日 - 2016年5月24日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • Changes of Immunoglobulin-bound Glycans in Patients with Gastro-Intestinal Cancers.

    Chihiro Dohi, Kazuhiro Nouso, Soichiro Ako, Yuuki Morimoto, Koji Miyahara, Hideaki Kinugasa, Nozomu Wada, Yasuto Takeuchi, Kenji Kuwaki, Hideki Onishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

    DDW 2016 

     詳細を見る

    開催年月日: 2016年5月21日 - 2016年5月24日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • 進行肝細胞癌に対するソラフェニブ治療における鉄マーカーとの関係性

    足立卓哉,能祖一裕,和田望,森元裕貴,竹内康人,桑木 健,大西 秀樹,中村 進一郎,白羽 英則,高木章乃夫,岡田裕之

    肝癌分子標的治療研究会 

     詳細を見る

    開催年月日: 2016年1月16日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • マイクロRNA阻害による肝癌化学療法治療効果増強の試み

    森元裕貴,能祖一裕,大山淳史,赤穂宗一郎,和田望,土肥千紘,竹内康人,安中幸,安中哲也,桑木健志,大西秀樹,池田房雄,中村進一郎,白羽英則,高木章乃夫,岡田裕之

    肝癌分子標的治療研究会 

     詳細を見る

    開催年月日: 2016年1月16日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 初発の単発肝細胞癌に対するラジオ波焼灼療法:生存予後が不良な集団の探索

    中村進一郎,能祖一裕,大西秀樹,桑木健志,竹内康人,和田 望,森元裕貴,安中哲也,池田房雄,白羽英則,高木章乃夫,山本和秀

    第51回 日本肝癌研究会 

     詳細を見る

    開催年月日: 2015年7月23日 - 2015年7月24日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 肝動注化学療法の効果と問題点

    大西秀樹,能祖一裕,山本和秀

    第51回 日本肝癌研究会 

     詳細を見る

    開催年月日: 2015年7月23日 - 2015年7月24日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • prediction of the recurrence of hepatocellular carcinoma by alpha-fetoprotein after radiofrequency ablation

    Dohi C, Nouso K, Miyahara K, Morimoto Y, Kinugasa H, Wada N, Takeuchi Y, Kuwaki K, Onishi H, Ikeda F, Nakamura S, Shiraha H,Takaki A, Okada H

    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 

     詳細を見る

    開催年月日: 2015年7月3日 - 2015年7月5日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • 肝細胞癌に対するラジオ波焼灼療法後の局所再発に寄与する因子と適切なsafety margin

    中村進一郎, 能祖一裕, 大西秀樹, 桑木健志, 竹内康人, 白羽英則, 歳森淳一, 萩原宏明, 小林功幸, 山本和秀

    日本超音波医学会第88回学術集会  日本超音波医学会

     詳細を見る

    開催年月日: 2015年5月24日

    記述言語:日本語   会議種別:口頭発表(一般)  

    researchmap

  • 腫瘍マーカーの推移から見た肝動注化学療法の早期治療効果予測

    大西秀樹、能祖一裕 、中村進一郎 、和田 望 、竹内康人 、桑木健志 、白羽英則 、山本和秀

    第51回 日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2015年5月21日 - 2015年5月22日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma : analysis focused on tumor location.

    Junichi Toshimori, Kazuhiro Nouso, Shinichiro Nakamura, Nozomu Wada, Yuki Morimoto, Yasuto Takeuchi, Kenji Kuwaki, Tetsuya Yasunaka, Hideki Ohnishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Kazuhide Yamamoto

    DDW 2015 

     詳細を見る

    開催年月日: 2015年5月16日 - 2015年5月19日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • 病態別に見た進行肝細胞癌に対する化学療法の効果

    大西秀樹, 能祖一裕, 山本和秀

    第101回 日本消化器病学会総会  日本消化器病学会

     詳細を見る

    開催年月日: 2015年4月23日 - 2015年4月25日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

  • 高度門脈浸潤合併進行肝細胞癌に対する放射線併用肝動注化学療法の効果

    大西秀樹, 能祖一裕, 山本和秀

    JDDW2014  日本肝臓学会

     詳細を見る

    開催年月日: 2014年10月23日 - 2014年10月26日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:神戸  

    researchmap

  • 縦隔腫瘍を合併した肝細胞腺腫の1 例

    土肥 千紘, 能祖 一裕, 和田 望, 森元 裕貴, 竹内 康人, 桑木 健志, 大西 秀樹, 池田 房雄, 中村進一郎, 白羽 英則, 高木章乃夫, 高木 弘誠, 吉田 龍一, 八木 孝仁, 山本 和秀

    第101回日本消化器病学会中国支部例会  日本消化器病学会

     詳細を見る

    開催年月日: 2014年6月21日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:岡山  

    researchmap

  • 肝細胞癌に対する定位放射線治療の有用性

    大西 秀樹, 能祖一裕, 中村進一郎, 勝井邦彰, 和田 望, 森元裕貴, 宮原孝治, 竹内康人, 安中哲也, 桑木健志, 白羽英則, 金澤 右, 山本和秀

    第50回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2014年6月5日 - 2014年6月6日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:京都  

    researchmap

  • 初発の多血性単発肝細胞癌に対するラジオ波焼灼療法:初回再発が同一区域内の症例は予後不良である

    中村進一郎, 能祖一裕, 大西 秀樹, 小林功幸, 桑木健志, 萩原宏明, 高木章乃夫, 白羽英則, 三宅康広, 安中哲也, 竹内康人, 和田 望, 山本和秀

    第50回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2014年6月5日 - 2014年6月6日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:京都  

    researchmap

  • Child C肝癌に対する当院における治療と、1年以上生存例の特徴

    桑木健志, 能祖一裕, 和田 望, 竹内康人, 安中哲也, 大西秀樹, 中村進一郎, 白羽英則, 高木章乃夫, 山本和秀

    第50回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2014年6月5日 - 2014年6月6日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:京都  

    researchmap

  • 肝悪性腫瘍に対するラジオ波焼灼療法時の疼痛対策;超音波ガイド下Glisson鞘内肝神経叢ブロックについて

    中村進一郎, 能祖一裕, 大西秀樹, 白羽英則, 桑木健志, 竹内康人, 和田 望, 石川慎一, 山本和秀

    第50回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2014年6月5日 - 2014年6月6日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:京都  

    researchmap

  • TACE不応後のHCCに対する治療戦略の検討

    和田 望, 能祖一裕, 中村進一郎, 森元裕貴, 竹内康人, 安中哲也, 桑木健志, 大西秀樹, 白羽英則, 高木章乃夫, 山本和秀

    第50回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2014年6月5日 - 2014年6月6日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:京都  

    researchmap

  • 肝癌におけるNotch シグナル活性化とその治療ターゲットとしての可能性

    白羽英則, 片岡淳朗, 堀口 繁, 岩室雅也, 永原照也, 内田大輔, 仁科慎一, 竹内康人, 桑木健志, 大西秀樹, 中村進一郎, 能祖一裕, 山本和秀

    第50回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2014年5月29日 - 2014年5月30日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 網羅的糖鎖解析による肝細胞癌バイオマーカーの検討

    宮原孝治, 能祖一裕, 森元裕貴, 衣笠秀明, 和田 望, 竹内康人, 安中哲也, 桑木健志, 大西秀樹, 池田房雄, 三宅康広, 中村進一郎, 白羽英則, 高木章乃夫, 天野麻穂, 西村紳一郎, 山本和秀

    第50回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2014年5月29日 - 2014年5月30日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:東京  

    researchmap

  • 肝動注化学療法からソラフェニブへの変更のタイミング

    大西 秀樹, 能祖一裕, 中村進一郎, 和田 望, 森元裕貴, 竹内康人, 宮原孝治, 桑木健志, 三宅康広, 白羽英則, 山本和秀

    第100回日本消化器病学会総会  日本消化器病学会

     詳細を見る

    開催年月日: 2014年4月23日 - 2014年4月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 加温MPT-TACEが奏功した肝細胞癌結節

    大西秀樹, 能祖一裕, 中村進一郎, 和田望, 森元裕貴, 宮原孝治, 竹内康人, 安中哲也, 桑木健志, 白羽英則, 山本和秀

    肝癌治療フォーラム 

     詳細を見る

    開催年月日: 2014年2月1日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:岡山  

    researchmap

  • C型慢性肝炎の肝線維化診断における高周波探触子を用いたASQの有用性?Fib-4 indexとの比較

    桑木健志, 中村進一郎, 和田望, 森元裕貴, 竹内康人, 萩原宏明, 安中哲也, 大西秀樹, 池田房雄, 白羽英則, 能祖一裕, 山本和秀

    JDDW2013  日本肝臓学会

     詳細を見る

    開催年月日: 2013年10月9日 - 2013年10月12日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 血清糖鎖マーカーによる進行肝細胞癌の予後予測

    宮原 孝治, 能祖 一裕, 森元 裕貴, 和田 望, 竹内 康人, 萩原 宏明, 桑木 健志, 大西 秀樹, 中村 進一郎, 白羽 英則, 天野 麻穂, 西村 紳一郎, 山本 和秀

    JDDW2013  日本肝臓学会

     詳細を見る

    開催年月日: 2013年10月9日 - 2013年10月12日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 進行肝細胞癌に対する肝動注化学療法の適応

    大西 秀樹

    第49回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2013年7月11日 - 2013年7月12日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:東京  

    researchmap

  • 進行肝細胞癌に対する肝動注化学療法の適応

    大西 秀樹, 能祖一裕, 中村進一郎, 和田 望, 森元裕貴, 竹内康人, 宮原孝治, 萩原宏明, 桑木健志, 三宅康広, 白羽英則, 山本和秀

    第49回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2013年7月11日 - 2013年7月12日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 肝細胞癌におけるAFP・AFP-L3分画の有用性

    竹内康人, 能祖一裕, 萩原宏明, 桑木健志, 三宅康広, 大西秀樹, 中村進一郎, 白羽英則, 高木章乃夫, 山本和秀

    第49回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2013年7月11日 - 2013年7月12日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:東京  

    researchmap

  • 肝ラジオ波焼灼術時の疼痛コントロール:超音波ガイド下Glisson鞘内肝神経叢ブロックについて

    中村進一郎, 能祖一裕, 大西秀樹, 白羽英則, 桑木健志, 萩原宏明, 竹内康人, 和田 望, 石川慎一, 山本和秀

    第49回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2013年7月11日 - 2013年7月12日

    記述言語:日本語  

    開催地:東京  

    researchmap

  • 当院における進行肝細胞癌に対するCDDP肝動注化学療法について

    萩原宏明, 能祖一裕, 中村進一郎, 和田 望, 竹内康人, 安中哲也, 桑木健志, 大西秀樹, 白羽英則, 山本和秀

    第49回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2013年7月11日 - 2013年7月12日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 血清糖鎖マーカーによる進行肝細胞癌の予後予測の可能性

    宮原 孝治, 能祖 一裕, 森元 裕貴, 和田 望, 竹内 康人, 萩原 宏明, 桑木 健志, 大西 秀樹, 中村 進一郎, 白羽 英則, 天野 麻穂, 広瀬 和子, 西村 紳一郎, 山本 和秀

    第8回日本肝がん分子標的治療研究会会  日本肝がん分子標的治療研究会

     詳細を見る

    開催年月日: 2013年6月21日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:石川  

    researchmap

  • 肝機能異常で発見され急速に進行した肝血管肉腫の一例

    和田望, 能祖一裕, 森元裕貴, 竹内康人, 萩原宏明, 桑木健志, 大西秀樹, 中村進一郎, 白羽英則, 山本和秀

    第99回日本消化器病学会中国支部例会  日本消化器病学会

     詳細を見る

    開催年月日: 2013年6月15日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:岡山  

    researchmap

  • Vp3/4を合併した進行肝細胞癌における放射線併用肝動注化学療法の治療効果

    大西 秀樹, 能祖 一裕, 山本 和秀

    第49回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2013年6月6日 - 2013年6月7日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • ソラフェニブ中止に伴う腫瘍進展に関する検討

    宮原 孝治, 能祖 一裕, 森元 裕貴, 竹内 康人, 和田 望, 萩原 宏明, 安中 哲也, 桑木 健志, 大西 秀樹, 池田 房雄, 三宅 康広, 中村 進一郎, 白羽 英則, 高木 章乃夫, 山本 和秀

    第49回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2013年6月6日 - 2013年6月7日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • 肝癌におけるRUNX3発現低下はNotchシグナルを介し癌幹細胞化とEMTを制御する

    白羽 英則, 片岡 淳朗, 堀口 繁, 岩室 雅也, 永原 照也, 内田 大輔, 仁科 慎一, 高木 章乃夫, 萩原 宏明, 桑木 健志, 大西 秀樹, 中村 進一郎, 能祖 一裕, 山本 和秀

    第49回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2013年6月6日 - 2013年6月7日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:東京  

    researchmap

  • ウイルス性慢性肝炎の肝線維化診断における6MHz探触子を用いたASQの有用性

    桑木 健志, 中村 進一郎, 竹内 康人, 萩原 宏明, 安中 哲也, 大西 秀樹, 池田 房雄, 能祖 一裕, 山本 和秀

    日本超音波医学会第86回学術集会  日本超音波医学会

     詳細を見る

    開催年月日: 2013年5月24日 - 2013年5月26日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:大阪  

    researchmap

  • 肝機能から見た肝癌化学療法の選択

    大西秀樹, 能祖一裕, 山本和秀

    第99回日本消化器病学会総会  日本消化器病学会

     詳細を見る

    開催年月日: 2013年3月21日 - 2013年3月23日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:鹿児島  

    researchmap

  • 3D/4Dプローブによる多血性肝腫瘤の造影超音波検査の有用性

    中村進一郎, 能祖一裕, 大西秀樹, 白羽英則, 桑木健志, 萩原宏明, 竹内康人, 山本和秀

    第99回日本消化器病学会総会  日本消化器病学会

     詳細を見る

    開催年月日: 2013年3月21日 - 2013年3月23日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:鹿児島  

    researchmap

  • 肝癌emtマーカーとしてのpivka-II

    白羽英則, 堀口 繁, 岩室雅也, 片岡淳朗, 永原照也, 内田大輔, 高木章乃夫, 萩原宏明, 桑木健志, 大西秀樹, 中村進一郎, 能祖一裕, 山本和秀

    第99回日本消化器病学会総会  日本消化器病学会

     詳細を見る

    開催年月日: 2013年3月21日 - 2013年3月23日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:鹿児島  

    researchmap

  • MPT-TACEで結節ごとに異なる経過をたどった多発肝細胞癌の一例

    大西秀樹, 能祖一裕, 中村進一郎, 和田望, 森元裕貴, 竹内康人, 萩原宏明, 安中哲也, 桑木健志, 白羽英則, 山本和秀

    肝癌治療フォーラム 

     詳細を見る

    開催年月日: 2013年3月8日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:岡山  

    researchmap

  • 肝臓領域の超音波がん検診へのカテゴリー判定導入の有効性と問題点

    桑木 健志, 竹内 康人, 萩原 宏明, 大西 秀樹, 中村 進一郎, 白羽 英則, 能祖 一裕, 山本 和秀

    第20回 JDDW  日本肝臓学会

     詳細を見る

    開催年月日: 2012年10月10日 - 2012年10月13日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:神戸  

    researchmap

  • 正常肝から発症し長期にわたり再発を繰り返す非B 非C 肝細胞癌の一例

    和田 望, 能祖一裕, 森元裕貴, 竹内康人, 安中哲也, 萩原宏明, 桑木健志, 大西秀樹, 中村進一郎, 白羽英則, 高木章乃夫, 山本和秀

    第48回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2012年7月20日 - 2012年7月21日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:金沢  

    researchmap

  • 3cm以下3個以内の肝細胞癌に対する肝動脈化学塞栓術後再発リスクの因子

    森元裕貴, 能祖一裕, 衣笠秀明, 萩原宏明, 桑木健志, 安中哲也, 大西秀樹, 池田房雄, 三宅康広, 中村進一郎, 白羽英則, 岩崎良章, 高木章乃夫, 山本和秀

    第48回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2012年7月20日 - 2012年7月21日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:金沢  

    researchmap

  • 肝ラジオ波焼灼術時の疼痛に対する超音波ガイド下Glisson 鞘内神経ブロックの有用性

    中村進一郎, 能祖一裕, 大西秀樹, 桑木健志, 萩原宏明, 白羽英則, 竹内康人, 森元裕貴, 和田 望, 山本和秀

    第48回日本肝癌研究会  日本肝癌研究会

     詳細を見る

    開催年月日: 2012年7月20日 - 2012年7月21日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:金沢  

    researchmap

  • 肝細胞癌において、カルボキシラーゼ活性低下は、SPARC発現を誘導し、細胞接着低下、EMT進行を引き起こす

    白羽英則, 堀口繁, 岩室雅也、片岡淳朗, 永原照也, 高木章乃夫, 萩原宏明, 桑木健志, 大西秀樹, 中村進一郎, 能祖一裕, 山本和秀

    第48回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2012年6月7日 - 2012年6月8日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:金沢  

    researchmap

  • HCV関連肝細胞癌の遺伝子学的成因についての検討

    竹内康人, 池田房雄, 森藤由記, 萩原宏明, 安中哲也, 桑木健志, 三宅康広, 大西秀樹, 中村進一郎, 白羽英則, 高木章乃夫, 岩?良章, 能祖一裕, 山本和秀

    第48回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2012年6月7日 - 2012年6月8日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:金沢  

    researchmap

  • 進行肝細胞癌に対する肝動脈化学寒栓療法におけるシスプラチン-リピオドール療法とエピルビシン-リピオドール療法の有用性における無作為化比較試験

    小林功幸, 能祖一裕, 桑木健志, 萩原宏明, 岩堂昭太, 植松周二, 大西秀樹, 中村進一郎, 詫間義隆, 宮武宏和, 高口浩一, 松本栄二, 金吉俊彦, 歳森淳一, 荒木康之, 山本和秀

    第48回日本肝臓学会総会  日本肝臓学会

     詳細を見る

    開催年月日: 2012年6月7日 - 2012年6月8日

    記述言語:日本語   会議種別:ポスター発表  

    開催地:金沢  

    researchmap

  • Sorafenibを含む集学的治療が奏功し、約1年間無増悪で経過した進行した肝細胞癌の1例

    半井明日香, 桑木健志, 竹内康人, 萩原宏明, 大西秀樹, 中村進一郎, 白羽英則, 能祖一裕, 山本和秀

    第106回日本内科学会中国地方会  日本内科学会

     詳細を見る

    開催年月日: 2012年6月2日

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:島根  

    researchmap

▼全件表示